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GENOME-SCALE GENETICS: LESSONS FROM FOUNDER 
POPULATIONS 
Eimear Elizabeth Kenny 
The Rockefeller University, June 2010 
 
The potential benefits of using population isolates in genetic mapping due to reduced 
genetic and environmental heterogeneity are offset by the challenges posed by these 
populations for traditional association methods. Population isolates often contain large 
amounts of direct and cryptic relatedness that confound baseline assumptions of 
independence among genotypes and phenotypes and require specialized approaches to 
account for this sample structure. We examined three such approaches for association 
testing: (i) scoring allele transmission to offspring within families (ii) incorporating a 
permutation-based association score between families into the test statistic and finally 
(iii) incorporation of a kinship matrix to capture the relatedness among all individuals 
into a mixed model to test for association. The mixed model approach had 88% power to 
rank the true SNP as among the top 10 genome-wide top 10 with 56% achieving genome-
wide significance, a >80% improvement over other methods. We then used the mixed 
model method for genome scans relating to metabolic traits and electrocardiographic 
measures in 2,906 related individuals from the Island of Kosrae, Federated States of 
Micronesia, who were previously genotyped for over 330,000 SNPs. We re-analyzed data 
for 17 published and 8 previously unpublished metabolic and electrocardiographic traits. 
We replicate seven genome-wide significant associations with known loci of plasma 
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides, thyroid 
stimulating hormone and C-reactive protein, with only one detected in the previous 
analysis of the same traits. We further report novel associations for height (rs17629022, 
p<2.1E-8), homocysteine (rs7481043, p<1.3E-8) and uric acid (rs2186571, p<1.8E-34), 
the latter two near relevant candidate genes. We demonstrated the increased power of 
mixed-models for handling hidden and direct relatedness in isolated cohorts and 
discovered three novel associations with height, homocysteine and urate levels. Our 
experiences in association testing in an isolated population can serve as a model for other 
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Chapter 1 : Introduction 
 
 
Genome-scale human genetics in 2010 
 
Rapid technological advances have accelerated the pace of human genetics in the past 
decade. Landmark accomplishments include the initial sequencing of the human genome 
in 2001 (Venter, 2001, Lander, 2001) and the completion of a “finished-grade” human 
genome reference sequence in 2004 (The Human Genome Project, 2004). Another 
landmark achievement was the release, in 2005, by the HapMap Consortium, of the first 
phase of an international effort to discover and expand the catalogue of human single 
nucleotide polymorphisms (SNPs). As a result, by August 2006, there were more than ten 
million SNPs in the National Center for Biotechnology SNP database (dbSNP), and 
examination of the HapMap SNP‟s, derived from four populations across three 
continents, revealed ~2M of them to be commonly polymorphic (The HapMap 
Consortium, 2005).  
 
These advances made possible the development of genome-scale genotyping platforms 
(“SNP chips”), which could, at a reasonable cost, assay 100K-1M common polymorphic 
genotypes across hundreds to thousands of individuals (Hirschhorn, 2005). These “SNP 
chips” were utilized for the design of genome-wide association studies (GWAS), in 
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which a dense set of SNPs across the genome is used to survey the most common genetic 
variation for a role in disease or to identify the heritable quantitative traits that are risk 
factors for disease. The underlying rationale for GWAS is the „common disease, common 
variant‟ hypothesis, positing that common diseases are attributable in part to alleles 
present in > 5% of the population (Reich, 2001). To achieve unbiased association signals, 
GWAS are mainly performed in cohorts of unrelated individuals, following a case/control 
design, a departure from decades of traditional variant discovery that relied on heritability 
within families. The first GWAS emerged in April 2005 (Klein, 2005), and to date, 
GWAS have reproducibly implicated over 700 genomic regions that modify the risk for 
over 120 complex disease and health-related phenotypes (Kruglyak, 2008, Manolio, 
2008).  
 
Taken together, this ongoing data bonanza has opened the window to myriad previously 
unknown variation in the human genome, and a current challenge in human genetics is to 
identify the specific variation that increases susceptibility to diseases. 
 
Complex disease gene mapping 
 
Human geneticists seek to understand the inherited basis of human disease and the 
underlying biology that contributes to disease pathophysiology. The goal is to gain 
clinical insights that could eventually improve treatment, produce useful diagnostic or 
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predictive tests, and to gain biological insights that could help elucidate the functional 
mechanisms underlying disease. Compared to rare Mendelian (or “monogenic”) diseases, 
complex (or “polygenic”) diseases (such as cancer, coronary artery disease and diabetes), 
or their underlying quantitative phenotypes (such as lipid levels and blood pressure), 
occur fairly commonly in human populations (see Figure 1.1). A substantial portion of 
individual differences in complex disease susceptibility are known to be due to genetic 
factors, however effects of age, gender, lifestyle, other environmental covariates, and the 
interactions between them, are also known to play a role. 
 
Detecting variants effecting complex disease 
 
The small genetic contribution of individual 
genes, combined with the confounding effects 
of non-genetic factors on phenotype measures, 
have meant that loci affecting complex diseases 
have been historically difficult to detect, with 
only a handful of examples prior to 2005 (for 
example, the APOEε2/ε4 polymorphisms 
affecting cholesterol levels and Alzheimer‟s 
disease (Zannis, 1981).  However, with the 
advent of GWAS undertaken in a large number 
Figure 1.1:  Schema comparing Mendelian 




of samples, many novel and convincingly associated loci have been mapped to numerous 
common polygenic disease and quantitative traits, for example, at least 32 loci for 
Crohn‟s disease and 95 loci for plasma lipid levels (McCarthy, 2008, Burnett, 2008, pers. 
comm. Sekar Kathiresan).   
 
Examination of the emerging loci have revealed some interesting biological insights. On 
one hand, GWAS have implicated many genes that had prior evidence from candidate 
gene studies to play a role in their respective traits. For example, of 23 loci found to be 
associated with lipid levels in one study, 11 implicate genes encoding apolipoproteins, 
lipases and other key proteins in lipid metabolism pathways (Mohlke, 2008). Further, 
>20% of loci discovered in GWAS for a variety of complex traits are known to also 
harbor mutations that cause monogenic diseases (Hirschhorn, 2009). On the other hand, 
GWAS have highlighted pathways whose relevance to a particular disease or trait was 
previously unsuspected, such as autophagy and interleukin-23-related pathways for 
Crohn‟s disease and the complement system for age-related macular degeneration, and 
this clustering into pathways is highly non-random (Raychaudhuri, 2009).  
 
Most of the time, the causal variant driving a GWAS signal is not the SNP directly 
assayed, but an unknown variant in the vicinity of the measured SNP, which is tagged by 
that SNP by virtue of residing on the same haplotypic background (being in “linkage 
disequilibrium” (LD)). Therefore, detecting a GWAS signal is merely the first step 
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toward discovering the underlying causal variant and various approaches can be taken to 
fine map the signal. One conventional approach is sequencing a region of arbitrary length 
around the signal peak across enough individuals to capture the causal allele. However, 
the larger the sequenced interval and number of individuals, the more variants 
discovered, making it difficult to distinguish the driver allele from the large number of 
passenger variants. This problem is exacerbated in cases where multiple, seemingly 
independent signals reside in close proximity along the genome (Haiman, 2007, Yeager, 
2007, Gudmundsson, 2007, Fellay, 2007, Duerr, 2006, Barrett, 2008, Romeo, 2008, 
Graham, 2007, Graham, 2008, Abelson, 2009, Plenge, 2007). Studies to identify the 
culprit causal variant(s) underlying the local peaks in association signals have shown 
mixed success, with only handful of causal variants identified so far (Burnett, 2008, 
Moffatt, 2007, Burkhardt, 2008) and many re-sequencing efforts proving unsuccessful 
(Lowe, 2007, Burfoot, 2008, Hafler, 2009). One possible explanation may be that the 
GWAS signal is driven not by a single common causal variant, but by multiple effects of 
rare variant in a synthetic association with common alleles assayed in the GWAS 
(Dickson, 2010). 
 
A limited fraction of heritability is captured by common variants 
 
Thus far, almost all GWAS discovered signals, both individually and in combination, 
have exhibited modest to small effects on their associated traits (with a few notable 
exceptions, such as age-related macular degeneration (Klein, 2005) and drug induced 
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liver injury (Daly, 2009). In fact, most traits examined so far in GWAS explain <5% of 
the fraction of heritability of that trait (Hirschhorn, 2009). A recent very well-powered 
GWAS of > 100K individuals for lipid levels, that expanded on a previous study with 
30K individuals, yielded ~65 extra loci, but added only 1-2% to  the total fraction of 
heritability explained for the trait (Kathiresan, 2009, pers. comm. Sekar Kathiresan). 
Further, there has been a scarcity of detected reproducible associations for some 
examined traits, especially neurological disorders, despite numerous GWAS efforts (Liu, 
2010, McMahon, 2010, Garriock, 2010).  
 
Many explanations to account for the source of this missing heritability have been 
suggested, including rare and/or structural variants, poorly captured by current GWAS 
platforms, gene-gene interactions, high signal-to-noise ratio in current GWAS strategies, 
the affects of environment in study populations, and“hidden” epigenetic effects (Manolio, 
2009). In response, the community is developing broader strategies for measuring such 
effects, for example, genome-wide analysis of epigenetic markers (Laird, 2010), a new 
generation of SNP chips (aided by the 1,000 Genomes Project) and tiling arrays targeting 
common and rare markers and structural variants, respectively, re-sequencing and 
sequencing-based population studies. Consensus is currently lacking, however, on which 
approaches and priorities for research will be most fruitful for pinning down the causes of 




Designing improved causal variant discovery approaches 
 
In designing improved approaches for discovering causal variants that contribute to 
complex disease, a number of considerations must be taken into account, such as: 
optimizing power for discovery, the expected impact of findings to the field and finite 
research dollars. The ideal strategy, therefore, would balance cost-effective, genome-
scale analysis with generality to different populations and multiple traits. In addition, the 
goal would be to redirect emphasis from discovering common, ancient variation (the 
target of current GWAS in outbred populations) to exploring rare or unique, newly arisen 
variants. To this end, renewed focus has been placed on study populations that play to 
these strengths and have been historically used for traditional genetic approaches, namely 
founder populations (Manolio, 2009).  
 
Founder populations in gene mapping 
 
Populations that have a small number of founders and/or are geographically or culturally 
isolated from other populations (“founder” or “isolated” populations) have a long history 
in genetic mapping studies of inherited disorders, particularly for the identification of 
rare, monogenic disease mutations (Arcos-Burgos, 2002, Heutink, 2002). Genetic 
isolates, such as the Finnish, Icelandic, Costa Rican, Old Order Amish, Jewish, Hutterite 
and Sardinian communities, have been successful in mapping not only rare monogenic, 
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but complex traits (Ober, 2001, Angius, 2002, Peltonen, 1999, Gulcher, 2001, Freimer, 
1996, Zamel, 1996, Abney, 2000, Aulchenko, 2004, van der Walt, 2005).  
 
Founder populations share a specific set of features as compared to outbred populations, 
namely reduced genetic diversity, reduced genetic and environmental heterogeneity, and 
often large, multi-generational pedigrees. The resulting reduction in allele heterogeneity 
has contributed to the success of genetic linkage and positional cloning approaches in 
isolated, founder populations (Peltonen, 1999, Gudmundsson, 2002, Lindqvist, 2000). 
These same properties that make isolated populations valuable for Mendelian trait 
genetics may be exploited for gene mapping of complex traits. Here we investigate the 
advantages and limitations of exploiting homozygosity in isolated populations for 
analysis of alleles affecting complex traits (Peltonen, 2000, Heutink, 2002, Gulcher, 
2001). 
 
Advantages of using founder populations in complex trait mapping 
 
Genome-wide association studies (GWAS), performed in outbred populations, have thus 
far identified many common variation contributing to complex diseases (Hindorff, 2009). 
One limitation in these studies is that rare variants that are not in linkage disequilibrium 
with the common variants assayed are usually not detected (Bodmer, 2008). However, 
when the populations analyzed in a GWAS have a substantial number of individuals that 
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share a recent common ancestor, not only common variants (Lowe 2009, Wang 2009), 
but sometimes also rare variants appearing at a higher frequency, or within a discernable 
haplotype structure, can be identified (Sabatti, 2009, Pollin, 2008, Kallio 2009). Further, 
while multiple rare mutations may segregate in an outbred population, founding events 
and subsequent population bottlenecks may reduce the allelic diversity such that a single 
mutation dominates the allelic spectrum in an isolated population.  
 
Founder populations typically exhibit a large amount of direct and cryptic relatedness, as 
compared to outbred cohorts, and this high degree of relatedness may result in increased 
homogeneity in phenotypes. In the case of small population isolates, well-documented 
multigenerational pedigrees can often be constructed, facilitating longitudinal analysis of 
both phenotypes and genotypes. Population isolates may also share similar environments, 
decreasing the signal-to-noise ratio for mapping. Finally, isolated populations often 
exhibit relatively high amounts of inbreeding producing an increased incidence of 





Inbreeding and the historical lack of random mating in founder populations violate 
assumptions of independence between genotypes and phenotypes confounding classical 
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association tests which measure the frequencies of alleles in disease cases versus 
controls. Specialized tests may account for any “known” relationships in the population, 
however hidden (relationships unreported or incorrectly specified) or cryptic relatedness 
(unreported or unknown distant relationships) may confound even specialized test 
statistics. Further, since consanguinity may be present, two alleles in a random individual 
may also be correlated. The hidden correlation in the data can cause an overdispersion in 
the null distribution of the naïve test scores for association and consequently, false 
positive associations. Hence, the major challenge for performing GWAS in isolated 
populations is to account for this non-random intra- and inter-individual correlation. 
 
Most GWAS have been thus far focused on outbred populations, and >75% utilize 
populations of European descent exclusively (Rosenberg 2010). This can lead to 
additional analytically challenges when studying non-European and/or founder 
populations. Several studies have found that markers typically used in GWAS are in 
various ways non-random (Nielsen 2004, Clark 2005). The focus on SNPs with high 
minor allele frequencies in populations of European ancestry in the initial selection of the 
markers for use on current GWAS platforms, in turn affects the relative proportion of the 
genome suited to mapping in different populations. This problem is exacerbated in 
founder populations, where the reduced genotypic heterogeneity further decreases the 




A recent trend for increasing power in GWAS is to adopt a genotype-imputation strategy 
(Halperin 2009). The approach relies on the assumption that two haplotypes, that are 
identical for a set of nearby markers, are likely to share the intervening chromosomal 
stretch identically by descent. Therefore, if one of the two haplotypes is genotyped more 
densely than the second haplotype, genotypes at the unmeasured positions on the second 
haplotype can be predicted (“imputed”). This approach requires the availability of a 
densely genotyped reference panel, such as the HapMap project (Frazer 2007). However, 
there is reduced portability of this approach to populations that are, compared to available 
reference panels, genetically distinct, such as founder populations. This leads to a 
reduction in imputation accuracy, and a consequent reduction in statistical power for 
imputation based association mapping.  
 
To take full advantage of the opportunities afforded for detecting causal variants in 
founder populations, there is a clear need for improved methods to overcome these 
technical challenges. To tackle this problem, we studied two distinctly different founder 
populations; a small, island-based, extreme isolate (the Kosrae islanders) and a large, 




A small, extreme founder population: Kosrae 
 
Kosrae is a Pacific Island member of the Federated States of Micronesia. It is located in 
the Pacific Ocean 370 mi (590 km) north of the equator, between Guam and the Hawaiian 
Islands, at 5°17‟ north and 162°58‟ east, longitude and latitude. Its land area is very 




) and the current day population of the island is 
~7,700 according to the most recent 2001 census.   
 
The history of Kosrae 
 
Although no historical records exist, it is believed that Kosrae was originally settled by a 
small number of founders (estimated to be 50) between 1,500-2,500 years ago, and 
subsequent estimates of the founder population size from current day genetic data from 
Kosrae support this (pers. comm. Dr Itsik Pe‟er and Sasha Gusev). Recent work has 
suggested that the island settlers were Polynesian, originally of aboriginal Taiwanese 






1804 and first visited in 1824. During the 19
th
 century, the combined effects of a typhoon 
(in 1835) and exposure of the native population to Western communicable diseases 
reduced the indigenous population from greater than 3000 to around 300 individuals by 
1888. Historical and genealogical records also indicate that there was admixture between 
native Kosraean females and 4-6 male Caucasian whalers from New England and Europe 
who visited the island in the mid to late 19
th
 century. However, current day estimates of 
Caucasian admixture on the island indicate that there is an average <1% Caucasian 
genome across all the islanders (Bonnen, 2010).  





Spain originally claimed Kosrae, but the island was purchased by Germany in 1899 
following the Spanish-American War. After World War II (WWII), the Federated States 
of Micronesia, including the islands of Kosrae, Truk, Yap, and Pohnpei, became a 
protectorate of the US government. At that time, the island population was estimated to 
be 1,550.  
 
A diet shift on Kosrae 
 
 
A number of visitors to the island in the 19
th
 and early 20
th
 century noted the natives to be 
thin. Prior to WWII, the Kosraens consumed a diet consisting mostly of fish, fruits and 
Figure 1.3:  Representation of the diet of indigenous Kosraens pre- (to the left) and post- (to the 
right) WWII. Pre-WWII, the indigenous islanders diet was high in starch (from tubers and fruit) and lean 
proteins (from fish) and polyunsaturated fats (from nuts). Post-WWII, with the supply of ready-to-eat meals 
from the US, the diet shifted to a high salt, high fat diet.   
15 
 
vegetables.  The designation of Kosrae as a US protectorate led to a drastic life style 
change on the island. Kosraens no longer had to fish for sustenance and assumed a more 
sedentary lifestyle. In addition, the diet on the island changed to a more Western diet with 
large quantities of high fat foods supplied through US aid (such as Spam, turkey tails, 
hamburgers, and ice cream). These changes resulted in a dramatically increased 
prevalence of obesity, an outcome similar to that seen in other indigenous populations 
exposed to a Western diet and lifestyle, such as the Samoans of Polynesia and the Navajo 
Native Americans of southwestern United States (Schumacher 2008, Lee 2008).  
 
The current health status of the islanders 
 
In response to the apparent growing epidemic of obesity on Kosrae, the United States 
Department of Health conducted a survey of the Island in two screenings in 1994 and 
2001. They collected information on a range of clinical traits that underlie the Metabolic 
Syndrome—a co-occurrence of 
metabolic abnormalities that groups 
together multiple traits that comprise 
serious risk factors to type 2 diabetes 
(5.8% prevalence in the US), coronary 
artery disease (4.8% prevalence and 
the leading cause of death in the US), 
Table 1.1: Incidence of Metabolic Syndrome, 
Obesity and Diabetes on Kosrea as compared to the 
US. Estimates are based on guidelines from 
1,2,3
Third 
Report of the National Cholesterol Education Program 
Expert Panel on Detection, Evaluation , and Treatment 
of High Blood Cholesterol in Adults 2003-2006. 
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stroke (1.6%) (Ervin 2009). These outcomes therefore have a significant negative impact 
on population health in developed countries.  
 
Prevalence estimates of metabolic syndrome were calculated for both 1994 and 2001 
health surveys and were found to be very high, rising from 27% in 1994 to 42% in 2001, 
a surge of more than 50% in a seven year span. Comparisons to other regions of the 
world show that Kosrae has one of the highest recorded rates of metabolic syndrome; 
roughly 3-, 4- and 2-fold higher than estimates for Koreans, Japanese and the United 
States, respectively (see Table 1.1) (Cameron 2004).  
 
A large, less extreme founder population: Ashkenazi Jews 
 
The Ashkenazi Jewish people (AJ) represent a founder population with a distinct well-
chronicled history. Although the AJ and Kosraen populations were both founded at a 
similar time in history, the two populations differ in many of their features. The AJ 
population is linked not by geographical isolation, but rather by: religion, language, 
customs and the traditional practice of endogamy. These practices have resulted in a 
distinct AJ genetic identity that has persevered despite thousands of years of migration 




The history of Ashkenazi Jews 
 
The Jewish people originated in the Middle East around the first millenium before the 
Common Era (BCE) and have had a long history of migration throughout the Middle 
East, North Africa and Europe, and more recently the Americas, Australia and South 
Africa. According to their area of long term residence, the modern Jewish people are 
divided into three groups; Sephardic Jews (who resided in Spain and Portugal until the 
15
th
 century), Middle Eastern Jews (who lived in contemporary Palestine and Israel, as 
well as Iraq, Iran and other Middle Eastern countries) and Ashkenazi Jews (who lived in 
Western and Eastern Europe).  
 
The Ashkenazi Jews (AJ) moved into Europe and then over the Alps into the cities of the 
Rhineland around the 9
th





 centuries, the AJ were expelled from the Rhineland, and resettled 
in Eastern Europe, mainly Poland, Lithuania and Russia. In the late nineteenth and early 
twentieth centurys, there were large AJ migrations westward (to America and Western 
Europe) and southward (to Australia and South Africa). Two important events in the 
twentieth century brought about the depletion of Jewry in Europe; the Jewish Holocaust 
of the WWII, which lead to the death of 6 million Jewish people and migration out of 
Europe, and the foundation of the state of Israel and the subsequent migration of Jews 
from all over the world to Israel. 
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Contemporary Ashkenazi Jews comprise ~13 million people, with the largest 
demographic centers being the United States (US), primarily the New York metropolis, 
and Israel where 5-6 and 3-4 million Jews reside, respectively. Around 90% of New York 
based Jews are of Ashkenazi descent, making Ashkenazi Jews the largest founder 
population in the United States.  
 
Ashkenazi genetic identity 
 
By Jewish religious law, Jewish identity follows matrilineal inheritance. However, 
studies of mitochondrial and Y-chromosomal polymorphisms provide strong evidence for 
both maternal and paternal transmission, supporting historical evidence for many 
generations of endogamy in this population (Ostrer, 2001). Further, studies of maternally 
inherited mitochondrial DNA have suggested that most Jewish communities were 
founded by relatively few women (Thomas, 2002), and that almost half the modern AJ 
population may be descendent from just four women (Behar, 2006). 
 
Since the middle of the 20
th
 century however, many Ashkenazi Jews have intermarried, 
both with members of other Jewish communities and with people of other nations and 






the world and raised them as Jews. Conversion to Judaism, rare for nearly 2,000 years, 
has become more common. Nonetheless, it has been shown that self-described Jewish 
ancestry is a major determinant of population genetic structure in European populations 
(Price 2008) and a recent study has shown that AJ individuals with different amount of 
AJ ancestry can form distinct identifiable groups based on genetic data alone (Need 
2009). 
 
Contemporary Ashkenazi Jewish populations have been studied extensively by the 
medical genetic community where at least 40 genetic conditions have been dissected 
(Ostrer 2001). Some of the mutations are found in multiple Jewish groups, such as the 
common mutation in the BRAC1 gene which increases susceptibly to cancer, which is 
likely to have originated before the dispersion of Jews (Bar-Sade 1998). However, in 
many cases the mutations are likely to have risen during migration and/or bottleneck 
events, where one or two prevalent founder mutations have occurred, for example, 
mutations in the GBA and the LDLR genes which cause Gaucher disease and 
hypercholesterolaemia, respectively (Diaz 2000, Durst 2001).   
 
Crohn’s disease in Ashkenazi Jews  
 
Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, 
which is thought to result from the effect of environmental factors in a genetically 
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predisposed host. An epidemiological feature of CD is that it has highest prevalence 
among individuals of AJ descent, occurring two to four times more frequently than in 
non-Jewish Caucasian populations. Three coding variants of the NOD2 gene have been 
reported as independent disease-predisposing mutations for CD. Confirmation studies 
have shown, however, that these susceptibility loci have similar allele frequencies and 
magnitudes of the effect and are unlikely to contribute to the excess prevalence of the 
disease in the AJ population. Therefore, involvement of other, yet unknown, genetic 
variants unique to this population is hypothesized. 
 
Improving methods for genome-scale genetics in founder populations 
 
The focus of my thesis was the development of new, optimally-powered strategies for 
analysis in founder populations. I started with the genome-scale genetic analysis of an 
extreme founder population, the Pacific Island of Kosrae. Analysis of this population 
(ongoing when I joined the Breslow lab in the summer of 2006) using existing methods 
had demonstrated reduced power in this cohort as compared to a similarly sized outbred 
cohort (Lowe, 2009). 
The primary goal of my thesis was to develop improved strategies for causal variant 
detection on Kosrae. We had previously shown abundant long genetic segments shared 
identically by descent on the island (Bonnen, 2006). Taking advantage of these long 
haplotypes, we developed a method for mapping causal haplotypes under a GWAS local 
signal peak (see Chapter 2) for dissecting multiple signals at the same locus, and 
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elucidated a putative causal variant. Next, we evaluated four specialized methods for 
performing GWAS in the context of relatedness using extensive genome-scale 
simulations (see Chapter 3), and demonstrated that mixed-models are best powered for 
these populations, Finally, leveraging these optimized strategies we performed a GWAS 
of 30 traits pertaining to metabolic disorders on Kosrae (see Chapter 4), reporting 10 
positive controls and 3 novel findings, one of which was refined by a factor of 4 with 
haplotypic mapping.   
 
The secondary goal, of my thesis was to determine whether analysis methods developed 
on Kosrae, could be utilized for the analysis of a less extreme founder populations, such 
as the Ashkenazi Jews. To demonstrate this, we performed a combined-analysis of seven 
Ashkenazi cohorts (see Chapter 5) and used mixed-models to perform a GWAS for 
Crohn‟s disease. We report two positive controls and one novel finding, where haplotypic 





Chapter 2 : Materials and Methods 
 
 
Kosrae study population collection 
 
The data collection and phenotype definitions on the island of Kosrae is explained in 
detail in Lowe et al 2009 and Kenny et al 2010 (Lowe 2009, Kenny 2010).  The screen 
was carried out by Steven Auerbach of the US Health Department, Maude Blundell of the 
Starr Center for Human Genetics at the Rockefeller University, and Vita Skilling of the 
Kosrae hospital, as well as the medical staff on the island of Kosrae.  Briefly, we 
surveyed 3,148 highly-related individuals from the Pacific Island of Kosrae in three 
separate screenings carried out in 1994 , 2001 and 2003 which represent >75% of the 
adult population on the island. All participants signed the informed consent prior to 
filling out questionnaires about medical and family history, physical examinations and 
blood drawings. Each person was assigned a unique identification number and filled out a 
questionnaire which noted the participant‟s sex, family data including listing of biological 
parents, siblings, and children, smoking status, alcohol intake, medications (the island has 
a limited formulary), self-reported ethnicity, age, and health status. The family data was 
used to derive the parity status of the women (0 to 5 and ≥6 children).  Finally, village of 
residence was recorded, where all individuals resided in one of five villages (Lelu, 




Measuring phenotypes pertaining to Metabolic Syndrome and cardiovascular 
conductance on Kosrae  
 
In all three screens, fasting blood was collected and centrifuged. Plasma and buffy coats 
were frozen and shipped to Rockefeller University, NY, for serological assays and DNA 
extraction. Phenotypes were measured for 30 metabolic and electrocardiographic traits; 
height (HGT), weight (WGT), waist circumference (WST), body mass index (BMI), 
percent body fat (PCF), leptin hormone levels (LEP), fasting blood sugar (FBS), insulin 
sensitivity (INS), Non-Insulin-Dependent Diabetes Mellitus (NIDDM), systolic blood 
pressure (SBP), diastolic blood pressure (DBP), total choleseterol (TG), low density 
lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), triglyceride 
(TG), Lipoprotein(a) (LPA), Campesterol (CAMP), Sitosterol (SITO), Lathosterol 
(LATH), C-reactive protein (CRP), thyroid stimulating hormone (TSH), glomular 
filtration rate (GFR), homocysteine (HOMO), folic acid (FLT), uric acid (URT), QT 
interval (QT), PR interval (PRD), QRS interval (QRS), Sokolow-Lyon voltage (SLV), 
Cornell voltage (CLV) and RR (inverse heart rate) interval (RRD).   
 
Anthropomorphic, Obesity, Diabetes and Hypertension:  
 
HGT (cm‟s or inches converted to cm‟s), WGT (lb‟s or lb‟s converted to kg‟s) and WST 
(cm‟s of inches converted to cm‟s) were measured for males age 24-80 and females age 
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22-80 who were considered to have reached their full adult height and weight. Individuals 
measured for HGT in more than one screening were omitted if their measurements 
differed by more than 4 cm‟s. BMI was calculated as WGT (kg) divided by HGT squared 
(m
2
). Obesity was defined as a BMI ≥30. PCF was measured using custom equipment 
(the “BodPod”, Tanita manufacturing company, Tokyo). FBS (mg/dL) was measured by 
fingerstick with a glucometer and pre-NIDDM and NIDDM were defined according to 
the American Diabetes Association (ADA) recommendations as impaired fasting glucose 
(FBG 100-125 mg/dL) or impaired glucose tolerance (GTT 140-199 mg/dL) and FBS  
126 mg/dL or OGTT2  200 mg/dL, respectively. Individuals under treatment with 
insulin or oral hypoglycemic drugs were excluded. The average of three seated SBP 
(mmHg) and DBP (mmHg) measures, taken manually with a stethoscope and 
sphygmomanometer, for individuals aged 20-75, was used in the analysis. Treatment for 
hypertension was taken into account by calculating an adjusted residual based on (Levy 
2000). 
 
A venipuncture was done for determination of serum levels of steroid hormones, lipids 
and other biomarkers. LEP levels (ng/mL) were determined using commercial 
radioimmunoassay (ELISA) in the Freidman Lab by Jeffery Winick, The Rockefeller 
University, NY, (Diagnostic Systems Laboratories, Webster, TX and Linco Research Inc, 
St Charles, MO). INS concentrations were measured on 740 randomly selected samples 
using a sensitive enzyme-linked immunosorbent assay (ELISA), at Graeme Bell‟s lab at 





TC (mg/dL) and TG (mg/dL) were measured either in the Breslow Lab, The Rockefeller 
Univeristy, NY, with commercially available enzymatic kits (Boehringer Manheim, 
Indianapolis, IN, Sigma Diagnostics, St. Louis, MO) or in the Rogosin Institute, NY, on a 
Roche COBAS Integra clinical chemistry analyzer using an enzymatic method, for the 
1994 and 2001/2003 screens respectively. For the 1994 screen, LDL and HDL 
quantification was not possible due to the lack of an adequate centrifuge on the island and 
the inability to ship serum overnight at 4 C.  As substitutes, the major apolipoproteins of 
LDL and HDL (APOB (mg/dL), and APOA-I (mg/dL), respectively) were measured 
using a standard double antibody immunoassay technique at Linda Youngman‟s lab at the 
Oxford University.  Both APOB and APOA-I are highly correlated with their respective 
cholesterol fractions, making them excellent surrogates (Bachorik 1997). For the 
2001/2003 screen, HDL (mg/dL) was also measured in the Rogosin Institute on a Roche 
COBAS Integra clinical chemistry analyzer using an enzymatic method, and LDL 
(mg/dL) was calculated using the Friedewald formula (Friedewald 1972): 
 
LDL (mg/dL) = TC(mg/dL) – HDL(mg/dL) – TG(mg/dL)/5 
 




Plasma plant sterol levels (CAMP (mg/dL) , SITO (mg/dL) and LATH (mg/dL)) were 
measured by gas liquid chromatography (Heinemann 1993) in the Seyhayek Lab, The 
Cleveland Clinic, OH, and plasma levels of CAMP, SITO and LATH were expressed as 
the ratio of sterol to total plasma cholesterol levels. LPA levels (mg/dL) were measured 
in the Rogosin Institute, NY, using the Polymedco assay (which is not sensitive to the 




TSH levels (IU/ml) were measured in the Rogosin Institute, NY. CRP (mg/dL) was 
measured using a chemiluminescent immunometric assay (Immulite 2000 High 
Sensitivity CRP, DPC, Los Angeles, CA) by the Rogosin Institute, NY. Positive outliers 
(>3 SD corresponding to >27.4 mg/L) were considered acute inflammatory reactions and 
excluded (n=28). All values below the functional sensitivity level of the assay (0.02) 
were Winsorized to 0.02 (n=36). Direct measures of GFR were not made for Kosrae 
subjects, and instead were based on plasma Creatinine (mg/dL) measured in the Rogosin 
Institute, NY, according to the widely used Modification of Diet in Renal Disease 
(MDRD) Study formula adjusted for a Chinese cohort: 
 




Individuals with GFR < 60 mg/dL (n=52) were considered “affected” for kidney disease 
and excluded. HOMO, URT, FLT levels were all measured in the Rogosin Institute, NY. 




During the 2001 screen, twelve-lead electrocardiograms were recorded at a paper speed 
of 50 mm per second in 1756 individuals using a Universal ECG (QRS Diagnostic LLC, 
Plymouth, MN).  De-identified paper electrocardiograms were scanned at high resolution 
using a Hewlett Packard 2840 All-in-one into digital images.  Quantitative measures of 
QT interval (ms), RR (inverse heart rate) interval (ms), QRS duration (ms), PR interval 
(ms), P wave duration (ms), SLV (mV), CLV (mV) and PQ interval (ms) were obtained 
using digital calipers in Rigel 1.7.3 (AMPS LLC, NY) from two cardiac cycles of lead II 
and one cycle each from V1-V5 (approximately orthogonal vector components). PR 
interval was measured from the onset of the P wave to the onset of the QRS complex and 
PQ interval from the offset of the P wave to the onset of the QRS complex. SLV was 
determined from the sum of the amplitude of the S wave in lead V1 and the R wave in 
lead V5 and CLV from the sum of the amplitude of R wave in a VL and S wave in V3. 
The QT interval is measured from the earliest onset of the QRS complex to the end of the 
T wave (in leads II and V5) and the RR interval is the R wave to R wave interval, and is 
the inverse of the heart rate. 
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Trait covariate and normality adjustments 
 
Statistical analysis was carried out using the JMP package (SAS Institute Inc., Cary, NC).  
All phenotyped and genotyped individuals between the ages of 18-88 were included in 
the analysis except where indicated above. All traits were separated by gender, adjusted 
for the effect of age (an adjusted residual based on age binned in 5-year intervals), 
outlier‟s ≥3 standard deviations from the mean were removed and Z-scores were 
calculated for each group. Pregnant women and non-Kosraen individuals were excluded. 
For monozygotic twins and individuals screened twice/thrice, the average Z-score was 
used. For some traits, the effects of additional covariates (BMI, smoking, village etc) 
were evaluated using either univariate logistic regression or multivariate logistic 
regression analysis to evaluate the effects of single or multiple covariates together, 
respectively, and the trait adjusted accordingly.  Z-scores may be log or square-root 
transformed for normality. Finally, Z-scores were pooled across groups for downstream 
analysis.  
 
Genotyping and quality control 
 
2,906 study participants were successfully genotyped on the Affymetrix 500K platform; 
data were generated at Affymetrix, South San Francisco, CA. Genotypes were called with 
the BRLMM algorithm and a minimum call rate of 95% was achieved. 446,802 SNPs 
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passed quality control filters and between ~122K-91K SNP‟s that were monomorphic or 
very rare (minor allele frequency (MAF) < 0.010 for each phenotype were also excluded. 
The final dataset yielded between 354,901-323,902 SNPs per phenotype with MAF > 




A first pass reconstruction of the extended pedigree of the 3,000-strong cohort included 
denser sampling of a further ~1,000 related non-genotyped individuals to fill out the 
pedigree and careful cross-referencing of patient records. The extended Kosraen pedigree 
spans eight generations including 4,300 people (living or deceased), where ~90% of the 
individuals are contained in a single very large kindred. Genome-wide SNP data were 
subjected to identity-by-state analyses and identity-by-descent estimation performed in 
PLINK (Purcell 2007) to correct and validate the pedigree structure. Full details of the 
pedigree construction are described elsewhere (Lowe 2009). The CraneFoot pedigree 
drawing software was used to visualize subsets of the extended pedigree. 
 
Kosrae trait heritability estimates 
 
Prior to undertaking a complete genome scan, to ensure that there were genetic factors 
involved in the quantitative traits under study, heritability (h
2
) was calculated. h
2
 is a 
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measure of the percentage of the variance in the trait that is attributable to the additive 
effects of genes, and is calculated based on the relationship between the known genetic 
correlations of relative pairs and their phenotypic similarity. 
 




The performance of candidate association methods was evaluated by analyzing simulated 
datasets constructed from real BMI phenotype data in which no genome-wide significant 
associations were found (Lowe 2009). For simulation, 1,000 SNPs were randomly 
selected from Kosraen 500k Affymetrix genotypes and 770 remained after filtering 
MAF>0.01. Using these SNPs, we generated a total of 770 genome-scale (~350K SNP's 
each) simulated datasets, in which each phenotype (BMI) was “spiked” to represent a 
dependency with one of 770 SNPs that contains an effect explaining an additional 2% of 
phenotypic variance. Each simulated dataset, comprising 2,906 Kosraen individuals, was 
deconstructed into a pedigree of 586 sibships of size ≥ 2 plus 240 individuals who were 
less than first cousins (a total of 2,007 individuals) that could be handled by all four 
methods. The four methods (FBAT, FBAT/Wald, Plink/QFAM-total and EMMAX) were 
used to perform association for each of the 770 sibship-structured, simulated datasets. 
Finally, in order to assess the full power of the EMMAX and FBAT/Wald methods, the 
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simulated datasets were also re-analyzed by these methods, this time including an extra 
310 individuals who did not fit into the sibship pedigrees (n= 2,317).  
 
Association methods:  
 
We performed comparative analysis for three different association approaches: a within-
family test vs. a within- and quasi-between- family test vs. a within- and between- family 
test. FBAT (version 2.0.2c) (Lange 2007) was chosen to represent a within-family test, 
QFAM-total procedure in PLINK software (plink version 1.05) (Purcell 2007) 
represented a within and partial between family model that utilizes a special permutation 
procedure to account for family structure. And we selected EMMAX (pre-release beta 
version) for representing a within- and between-family test, which handles all the 
relatedness of the cohort (Kang 2010). As both FBAT and QFAM/PLINK do not support 
association mapping in complex pedigree structures, the pedigree was broken down into 
sibships (siblings without parents) as described previously (Lowe 2009) and these 
sibships were used for testing each association method. We tested each representative 
tool under additive models and with moderate parameters to optimize its behavior of 
association mapping. For FBAT, we set minsize to 3, which is the required parameter of 
minimum size of family to include for analysis, without loss of any data and biallelic test 
under an additive model was performed with the default settings. QFAM was run under 
the PLINK framework with the parameter of qfam-total, and the aperm parameter was 
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also included for adaptive permutation. EMMAX analysis was performed by constructing 




We evaluated the performance of each method by two metrics. First, a rank-based score 
measured the p-value rank of the ground truth SNP in its own dataset. We compared the 
aggregate of rank of ground truth SNP for the three different association methods and 
considered the one that assigns more high ranks to ground truth SNPs to be the more 
powerful method. The second metric was a p-value-based score, which measures the p-
value of the ground truth SNP in its respective dataset. With the sum of ground truth 
SNPs exceeding a particular p-value threshold, we alternatively compared the power of 
each method.  
 
Association mapping of Kosraen traits using EMMAX 
 
EMMAX was selected for association study of 31 Kosraen traits where low frequency 
genotypes (MAF>0.01) were removed. A kinship matrix which captured the relatedness 
between all pairs of phenotyped individuals for each trait was incorporated into the 
EMMAX mixed model to test for association. Minimal score inflation was seen in the 
nominal p-values for all traits. 
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 Since there is a high degree of linkage disequilibrium in our data, we determined a 
genome-wide significance threshold by first extrapolating an approximate testing burden 
from the trait data. The median minima p-value from 14 null traits was 1.6x10
-6
, 
indicating an estimated testing burden of ~310,000 (actual number of tests was 
~386,000). The genome-wide significance threshold for to account for multiple testing 
for each trait was determined by Bonferroni correction based on the estimated testing 
burden, i.e. 0.05/310,000 = p≤ 1.6x10
-7
. A study-wide significance threshold that also 
accounts for testing multiple traits in the same study was determined conservatively using 
the Bonferroni correction: 1.6x10
-7




For very strongly associated signal peaks ≤ 10
-20
 (such as those for URT, PPS, LPA), we 
derive a more conservative empirical genome-wide significance threshold. The empirical 
genome-wide significance threshold was calculated by the following steps: (i) phenotypes 
were randomly permuted between individuals 1,000 times, accounting for family 
structure, in order to generate 1,000 permuted genotype/phenotype datasets (ii) genome-
wide association analysis was performed for each permuted dataset, and the minimum p-
value recorded, (iii) the first percentile of the 1,000 genome-wide permuted minima was 
set as the empirical genome-wide significance threshold (1.4 x 10
-10
). We considered a 
nominal p-value observed in the real data to be genome-wide significant if it exceeded 




Identity-by-descent haplotype mapping in Kosrae 
 
Identifying local haplotypes:  
 
Genotypes for the entire Kosraean population were phased using the BEAGLE-trio 
algorithm in one run according to the recommended parameters: 1 sample, 10 iterations 
(Browning 2008). An 11 Mb region underlying the genome scan signal peak (chr2:36-
47MB) was excised for each individual and analyzed for pairwise IBD matching by the 
GERMLINE algorithm (Gusev 2008). GERMLINE first identifies short “seed” regions of 
30 SNPs that are identical across subsets of the population.  Pairs of matching individuals 
at a seed are then extended across flanking regions that are nearly-identical. We 
registered haplotypes whenever pairwise comparison revealed a window of allele-call 
identity at least 500 kb in length with up to 1% mismatch allowed for genotyping error 
 
Haplotype clustering criteria:  
 
Moving from the pairwise IBD segments generated by GERMLINE to a comprehensive 
set of unique haplotypes required a novel clustering approach. We clustered in two ways: 
first we identified sets of individuals that may have any amount of common sharing 
within a region of interest; then we mapped the specific sharing boundary positions 
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among individuals of interest. The first clustering methodology borrowed a graph-theory 
approach for finding connected components. We constructed a graph where each 
individual is represented as a vertex and a shared IBD segment across two individuals in 
the region of interest forms a simple undirected edge between their respective vertices. A 
connected component is a sub-graph in which any two nodes are connected by a path; in 
our IBD graph, a maximally connected component represented all individuals that shared 
a common haplotype. We used this approach to seek out sets of individuals sharing 
common haplotypes whose mean phenotype deviated significantly from the expected, 
designated “affected individuals”. We devised a second clustering methodology to 
identified the specific physical boundaries of the unique region that is shared among 
multiple individuals from the pairwise sharing data. Conceptually, this algorithm 
iteratively layered pairwise shared segments between common individuals while keeping 
track of the physical positions where each individual initiates or ends sharing with the 
haplotype. Upon analyzing all pairwise shared segments, the algorithm generated, for 
each marker along the region of interest, the sets of individuals that share a common 
haplotype at that marker. These results were used to identify any region which was 
shared exclusively by affected individuals. 
 
PPS signal peak fine-mapping 
 
An 11 Mb region underlying the genome scan signal peak (chr2:36-47MB) was excised 
for each individual and analyzed for pairwise IBD matching by the GERMLINE 
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algorithm (Gusev 2008). All 13 exons of the ABCG5 and ABCG8 genes including their 
splicing donor/acceptor flanking sequences were PCR amplified and sequenced using the 
Applied Biosystems 3730xl sequencer. Sequencing chromatographs were analyzed by 
using the FinchTV 1.4.0 and DNASTAR Lasergene 8 software. 
 
URT signal peak fine-mapping 
 
93,629 distinct haplotype clusters were identified after filtering for haplotype clusters of 
≥0.01 frequency ≥500kb in length. The haplotype clusters were associated to uric acid 
levels using EMMAX (see above) and a 13 genome-wide significant haplotypes 
spannning chr11:36.2-94.2MB emerged (p<8.52x10
-8
), with a chr11: 63.4-65.2 sub-
region being most significantly associated (p<9.06x10
-46
) .  
 
Ashkenazi Jewish study population collection 
 
Genome-scale genotype data was collected for 3,573 individuals of self reported 
Ashkenazi Jewish (AJ) descent from seven different centers in New York, NY and Tel 
Aviv, Israel. The data consisted of called genotypes assayed on either the Illumina 300k, 
550K or IM or Affymetrix 500k or 6.0 platforms. The combined sample contains 966, 
449, 554, 101 and 297 individuals who have been diagnosed with Crohn‟s disease, 
Parkinson‟s disease, Schizophrenia, Dystonia and Non-Insulin dependent Diabetes, 
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respectively. The sample also contains 1,680 “control” individuals for each of these 
diseases.   
 
Constructing a combined AJ dataset for genome mapping 
 
Combining all AJ datasets: 
 
All datasets were converted to PLINK format and low quality genotypes (missingness 
>0.02) or individuals with missing genotypes (missingness >0.02) were excluded (--
missing flag). Also excluded were genotypes with minor allele frequency <0.01 (--geno 
flag). Ambiguous SNP‟s (those that are A/T or C/G) were removed from individuals 
assayed on Affymetrix platform. If gender information was missing, it was inferred using 
PLINK (--impute-sex flag) where the X chromosome SNPs were provided. Duplicate 
samples within and between datasets were detected (n=9) using PLINK (--genome flag) 
and one of the pairs was removed. Homozygous heterozygote SNP‟s were detected and 
set to missing. Finally the eight datasets were merged in PLINK (--merge flag) to yield a 
combined dataset of partial genotyping across the Affymetrix and Illumina platforms for 
3,564 individuals. AJ ancestry for all samples was assessed by principal components 
analysis across ~23K unlinked SNPs in the sample, including Jewish Hapmap AJ 
samples (n=34), Hapmap CEU samples (n=164), and other non-AJ Jewish or middle 
eastern samples from the Jewish HapMap and Human Genome Diversity panel (Ostrer 
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2010). ~600 individuals were determined to have significant non-AJ ancestry and were 
excluded from the analysis.  
 
Constructing an AJ reference panel for imputation: 
 
We constructed an AJ reference panel for 100 AJ individuals who had been typed on both 
the Affymetrix 6.0 and Illumina 1M platforms, resulting in 1,778,360 genotyped SNP‟s 
for these individuals. Genotypes with >0.02 missingnes, homozygous heterozyotes and 
low frequency SNPs (MAF <0.02) were excluded. Ambiguous SNP‟s (A/T or C/G) on 
the Affymetrix platform were also excluded. We attempted to recover these by BEAGLE 
(Browning 2008) imputation, accepting on high quality imputed genotypes (r
2
>0.9). 
Finally, 2 individuals who were discordant >0.008 were also excluded from the reference 
panel. The final panel consisted of 1,328,536 genotypes in 98 individuals.  
 
 Imputing missing genotypes in the combined AJ dataset using the reference panel 
 
Missing genotypes in the combined AJ dataset were imputed from the constructed AJ 
reference panel using BEAGLE. Genotypes that were either poorly imputed (r
2
<0.9) or 
had low frequency (MAF <0.01) were excluded from the subsequent analysis. The final 
dataset contained 1,068,161 SNP‟s in 2,860 individuals.    
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Mapping of AJ traits using EMMAX 
 
Association for Crohn‟s disease (CD) was performed using EMMAX as described above. 
In each case, the case‟s for CD (n=781) were compared to a combination of non-disease 
controls and disease non-case controls (n=2,079 and n=2,411, respectively). To control 
for strong genetic effects, the LRRK2 region was excluded from the CD analysis. To 
account for batch effects between different platforms and/or datasets the association 
between every pair of datasets (partitioned by case and control) were analyzed and 
significant SNP‟s (<10
-4




All analysis of the simulated datasets and real data were performed on a 3.0 GHz Intel 
Xeon dual core 64-bit cluster containing 100 nodes (with 4 processors each), where each 












Rapid technological advances in genomics over the last few years have focused on 
identifying common genetic variants affecting complex disease risk. To date genome-
wide association studies (GWAS) have reproducibly implicated over 700 genomic 
regions that modify the risk for over 120 complex diseases and health-related phenotypes 
(Kruglyak, 2008, Manolio, 2008) . However, identifying the culprit causal variant(s) 
underlying these local peaks in association signals remains a challenging task with only a 
handful of causal variants identified so far (Burnett, 2008, Moffatt, 2007, Burkhardt, 
2008). One conventional approach is sequencing a region of arbitrary length around the 
signal peak across enough individuals to capture the causal allele. However, the larger the 
sequenced interval and number of individuals, the more variants will be discovered 
making it difficult to distinguish the driver allele from the large number of passenger 
variants. This problem is exacerbated in cases where multiple, seemingly independent 
signals reside in close proximity along the genome. Recent examples of multiple alleles 
include the 8q24 region for prostate cancer(Haiman, 2007, Yeager, 2007, Gudmundsson, 
2007), 6p21 region for HIV-1 viral setpoint (Fellay, 2007), the IL23R, 6p25 and 17q21 
regions for Crohn‟s disease (Duerr, 2006, Barrett, 2008), the PNPLA3 region and 
nonalcoholic fatty liver disease (Romeo, 2008) the IRF5, STAT4 and TNFAIP3 regions 
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for systemic lupus erythematosis (Graham, 2007, Graham, 2008, Abelson, 2009) and the 
6q23 region for rheumatoid arthritis (Plenge, 2007).  
 
We introduce a method for exposing a causal variant in a region of a genome scan signal 
that begins with the identification of the full set of haplotypes underlying the signal peak. 
We assume that a causal derived allele enters a population as a mutation on the 
background of an ancestral chromosome or haplotype and, under an infinite sites model, 
that the allele is likely to have mutated only once on that unique ancestral haplotype 
(Gabriel, 2002, Watterson, 1975). Haplotypes are subject to decay over time by 
recombination events that occur with each generational meiosis, however mutations that 
have occurred relatively recently may still be observable as common haplotypes. If 
individuals in a population harbor a causal derived allele inherited from a recent 
progenitor, they likely also share a very long segment of the ancestral DNA around the 
allele. We previously developed the Genetic Error-tolerant Regional Matching with 
LINear-time Extension (GERMLINE) algorithm (Gusev 2008) which performs pairwise 
identity-by-descent matching to identify long shared genomic segments in a population. 
Here, we combine GERMLINE with a novel clustering algorithm which groups similar 
shared haplotypes to identify any common co-inherited haplotype that might associate to 
a signal peak. By selecting long co-inherited haplotypes our approach avoids the 
confounding effects of long range linkage disequilibrium faced by methods based on 
shorter haplotypes (de Bakker, 2005, Durrant, 2004, Horvath, 2004, Schaid, 2002, 
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Verzilli, 2006) and a reduced multiple test burden relative to other similar methods (Lin, 
2004, Tregouet, 2009, Laramie, 2007, Purcell, 2007, Albrechtsen, 2009).  
We tested our method in an extreme isolate founder population where we had previously 
shown abundant long haplotype segments shared between individuals (Gusev, 2008, 
Bonnen, 2006). The Pacific Island of Kosrae, in the Federated States of Micronesia, was 
likely settled 2,500-1,500 years ago by individuals of Asian ancestry and Islanders have a 
high incidence of obesity and diabetes (Gray, 2009, Friedlaender, 2008, Kayser, 2008, 
Shmulewitz, 2006, Lowe, 2009). We focused on plasma plant sterol (PPS) levels, which 
were ascertained as part of a broader study to examine genetic causes of the metabolic 
syndrome on the island (Lowe, 2009). 
 
 Plant sterols are a dietary source of neutral sterols that are structurally similar to 
cholesterol (Ostlund, 2002, Heinemann, 1993). Studies of the rare disorder 
phytosterolemia, which is characterized by extremely high PPS and severe premature 
atherosclerosis, have implicated mutations in the ATP binding cassette subfamily G 
members 5 or 8 (ABCG5 or ABCG8) genes (Berge, 2000, Hubacek, 2001). The 
ABCG5/ABCG8 genes form an obligate heterodimer that has been shown to be involved 
in intestinal absorption and biliary excretion of neutral sterols, including plant sterols and 
cholesterol (Graf, 2003). As such, PPS are considered to be a biomarker for dietary 
cholesterol absorption and changes in the balance of cholesterol absorption and secretion 
have been suggested to be atherogenic (Rudkowska, 2008, Sudhop, 2002). Further, it is 
unclear whether moderately elevated PPS may themselves affect cardiovascular risk 
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(Silbernagel, 2009, Fassbender, 2008, Chan, 2006). We had previously reported that 
13.8% of Kosraens are carriers of an ABCG8 exon 2 frameshift mutation leading to a 
nonsense ABCG8 codon (nonsense ABCG8 mutation) which results in a premature 
truncation and non-functional protein. The ABCG8 nonsense mutation was shown to 
effect a 30%-50% increase in plasma levels of campesterol and sitosterol, the two most 
abundant plant sterols in plasma (Sehayek, 2004).  
Here, we validated the ABCG8 exon 2 nonsense mutation effect in a larger Kosraean 
cohort of ~3,000 individuals and performed an association analysis of PPS levels, which 
implicated a second strong signal at the same locus. We analyzed identity-by-descent 
(IBD) shared genetic segments using the GERMLINE software to dissect the full set of 
long-range haplotypes in this region and identified a distinctive 526 kb haplotype, 
independent of the ABCG8 nonsense mutation, which is carried by 1.8% of Kosraens and 
associated with a striking 100% increase in PPS levels. Sequencing of the 
ABCG5/ABCG8 genes in carriers of the 526 kb haplotype revealed a novel ABCG5 
D450H missense mutation, a plausible putative causal variant in this haplotype. These 
findings exemplify the power of haplotype analysis in resolving the effect of multiple 






Analysis of multiple signals on Chr2p21 for PPS 
 
We performed a GWAS in 1,423 related individuals (who were phenotyped for PPS 
levels) on the Pacific Island of Kosrae with genotypes from the Affymetrix 500k array 
and incorporating the ABCG8 nonsense mutation we had separately genotyped. The 
analysis revealed 48 SNPs, all on chromosome 2p21, that surpassed an empirical 
permutation-based threshold (see methods for details) of genome-wide significance at a 
nominal p-value of 110
-10
 (Figure 3.1(A)). The strongest signal confirmed the 
association of the ABCG8 nonsense mutation (p<510
-39
) to PPS levels and validated our 
previous finding in a subset of this cohort (Sehayek, 2004). Closer examination of the 
signal at chromosome 2p21 revealed a broad signal peak with genome-wide significant 
signals for PPS extending up to 10 Mb upstream and 1 Mb downstream of the 
ABCG5/ABCG8 locus (Figure 3.1(B)). To determine whether this extended signal was 
entirely accounted for by the ABCG8 nonsense mutation, we reanalyzed the association 
of the PPS phenotype conditioned on the ABCG8 nonsense mutation genotype (Figure 
3.1(C)).  
Multiple strong signals that exceeded the genome-wide significance threshold up- and 
downstream of the ABCG8 locus persisted and suggested the presence of additional 




Figure 3.1 Stepwise conditional analysis of a genome-wide plasma plant sterol (PPS) levels: (A) 
Unconditioned genome-wide association of PPS. Association analysis was performed as described in the 
methods section. The red line marks the threshold of empirical genome-wide significance. (B) 
Unconditioned association of PPS in a 11Mb interval on chromosome 2 surrounding the genome-wide peak 
signal and the ABCG5/ABCG8 genes. Maroon square indicates the ABCG8 nonsense mutation with the 
best signal. Red shaded area marks the ABCG8 locus. (C) Association of PPS in the same chromosome 2 
interval after conditioning for the ABCG8 nonsense mutation. Blue square indicates the SNP (rs12185607) 
with the best signal. (D) Association of PPS in the same chromosome 2 interval after conditioning for both 
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) ~250 kb downstream of the ABCG5/ABCG8 locus. To examine 
the possibility of additional independent signals, we analyzed the association of PPS 
phenotype conditioned on both the ABCG8 nonsense mutation and rs12185607. 
Conditioning of PPS on both variants abolished statistically significant signals across the 
genome, as shown in Figure 3.1(D), and specifically at the chromosome 2p21 interval. 
We observed that the effects of the ABCG8 nonsense mutation and rs12185607/G were 
in the same direction and the minor alleles were the risk alleles in both cases. Given the 
carrier rates of 11.1% and 1.8% of the ABCG8 nonsense mutation and the 
rs121185607/G minor allele, respectively, we expected to find 5-6 Islanders carrying 
both alleles. We observed only two individuals (p=0.076 assuming independence) who 
were carriers of both minor alleles. Therefore, our findings suggested the presence of two 
independent variants effecting PPS at the chromosome 2p21 locus. 
Table 3.1 Linkage equilibrium between the ABCG8 
nonsense mutation and rs12185607/G allele 
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Systematic identification of a novel PPS 
haplotype at chr2p21 
 
To capture the second causal allele on 
chromosome 2p21 we devised an analysis 
pipeline to systematically identify all common 
haplotypes in the region (see Figure 3.2). The 
11 Mb signal region on chromosome 2p21 
(chr2:36-47MB) around the ABCG5/ABCG8 
locus was excised and common haplotypes 
were identified by IBD matching using 
GERMLINE (Gusev, 2009). The IBD 
segments were at least 500 kb in length and 
allowed for up to 1% mismatching due to 
genotyping error. Next, we clustered groups 
of similar haplotypes using similarity 
measures and binned together sets of 
individuals that had common sharing within 
the 2p21 region. These efforts identified 
3,681,003 pairs of individuals that shared 
one or more IBD matching segments >500 
Figure 3.2 Schema of the analysis pipeline 
for novel PPS haplotype discovery, 
refinement and validation. BEAGLE-trio 
phased haplotypes for the chromosome 2 
region (36-47MB) were excised and analyzed 
with GERMLINE to detect matching 
pairwise IBD segments. Overlapping 
segments that matched across the population 
were clustered and these the mean phenotype 
of cluster members was assessed. One cluster 
containing a 1.3MB haplotype strongly 
associated to high PPS levels. Careful 
comparison of haplotypes in that cluster 
revealed a unique ~526kb shared segment 
carried by 52 individuals. The CRANEFOOT 
software was used to visualize the ~526kb 




kb in length. These matched pairs clustered to 233 bins of common sharing with >99% 
sequence identity (see Figure 3.3). We found a single cluster containing 44 individuals 
that shared a 1.3 Mb haplotype strongly associated with PPS levels (p<4x10
-65
). This 
haplotype was shared by eight additional individuals who were not phenotyped for PPS 
levels. We mapped the specific sharing boundaries of the haplotype to a 526 kb sub-
region (chr2:43.8-44.3 Mb) that was unique to this group of 52 individuals (see Figure 
3.4(A)). Fourteen individuals (six phenotyped), who were carriers of rs12185607/G but 




Figure 3.3 Histogram of haplotype cluster sizes. The x-axis shows the 
haplotypes binned by the number of haplotypes in each cluster and the number 




Figure 3.4(A) Annotated genes on the background of the 526 kb haplotype.  The novel PPS haplotype 
(indicated as a grey bar) extends over a 526kb region on chromosome 2p21 that includes the ABCG8 and 
ABCG5 candidate genes (indicated by a black dashed square) and also fully or partially 5 other annotated 
loci (Ensembl Homo sapiens version 54.36p (NCBI 36) Chromosome 2 : 43,000,000 .. 45,000,000 
[54]).(B) Effect of the ABCG8 nonsense mutation and 526 kb haplotype carrier state on PPS. Fasting 
plasma levels of campesterol and sitosterol were determined as described in the Methods section. Values 
shown are Mean  SEM. 
 
 
Clustering of the novel PPS haplotype in three Kosraean pedigrees 
 
We investigated the family structure of the 52 carriers of the 526 kb haplotype.  This 
haplotype segregated in three kindreds containing 110 genotyped individuals from the 
same village, and was present in one unrelated individual (see Figure 3.5). There were 
two carriers of both the 526 kb haplotype and the ABCG8 nonsense mutation, each 
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inherited from a different parent. We performed admixture analysis, using the 
ANCESTRYMAP algorithm (Patterson, 2004) trained on four Hapmap phase III 
reference panels (CEU, CHB, JPT, GIH) to examine the ancestral origin of the 526 kb 
haplotype, and found no evidence of admixture in the region. 
 
The three kindreds segregating the PPS haplotype came from the same village, opening 
the possibility that a shared local environment or other non-genetic factor might cause 
increased PPS levels in the whole village and, hence, false positive association signals 
among this sub-population. To control for any confounding local environment in the 
village, we coded PPS haplotype carrier status as an allele (1=carrier, 0=non-carrier) and 
performed association analysis with PPS levels. 89 phenotyped villagers who fell into 39 
nuclear families were analyzed with PLINK/QFAM and the PPS haplotype remained 








Figure 3.5 Segregation of PPS haplotype in three kindreds from one village. The pedigree structure of 146 individual forming three kindreds and one 
unrelated individual from the same village on Kosrae. PPS haplotype carriers are shown in horizontal strips. Non-carriers are shown in white. 36 non-genotyped 




Phenotypic effect of the 526 kb haplotype 
Previous analysis in a subset of the Kosraen cohort revealed that carriers of the ABCG8 
nonsense mutation are characterized by a 30-50% increase in plasma campesterol and 
sitosterol levels, but no alteration in plasma cholesterol levels (Sehayek, 2004). Here, we 
have examined the effect of the ABCG8 nonsense mutation and the 526 kb haplotype on 
PPS and plasma lipid levels in the entire cohort. As shown in Figure 3.4(B), carriers of 
the ABCG8 nonsense mutation had a 50-54% increase in mean plasma campesterol (2.00 
± 0.87 vs. 1.33 ± 0.52) and sitosterol (1.85 ± 0.81 vs. 1.20 ± 0.48) levels compared to 
non-carriers (in both cases p<0.0001). Also shown in Figure 3.3(B), carriers of the 526 
kb haplotype had a 109-117% increase in mean plasma campesterol (2.78 ± 1.01 vs. 1.33 
± 0.52) and sitosterol (2.61 ± 1.00 vs. 1.20 ± 0.48) levels compared to non-carriers (in 




















ABCG8 carriers vs 
PPS carriers 
Lath:Chol 
1.50 ±  0.66 
(1900) 
1.52 ± 0.67 
(1687) 
1.33 ± 0.55  
(213) 














170.2 ± 34.48 
(315) 
167.55 ± 34.92 
(52) 
0.022 N.S. N.S 
LDL-c 
(mg/dL) 
102.1 ± 29.54 
(1899) 
101.63 ± 29.3 
(1645) 
105.42 ± 30.63 
(210) 
100.84 ± 30.73 
(44) 
N.S. N.S. N.S 
ApoB 
(mg/dL) 
86.97 ± 21.32 
(1884) 
86.65 ± 21.31 
(1621) 
88.53 ± 21.64 
(219) 
89.7 ± 19.8 
(35) 
N.S. N.S. N.S 
HDL-c 
(mg/dL) 
38.28 ± 11.04 
(1899) 
38.09 ± 10.95 
(1645) 
38.77 ± 11.36 
(210) 
42.00 ± 9.93 
(44) 
N.S. N.S. N.S 
ApoA1 
(mg/dL) 





118.07 ± 26.5 
(219) 
122.21 ± 25.3 
(35) 
N.S. N.S. N.S 
TG 
(mg/dL) 





95.58 ± 39.02 
(315) 
93.26 ± 36.32 
(52) 
0.05 N.S. N.S 
Table 3.2 Lathosterol:cholesterol and other plasma lipid levels. ANOVA analysis of lathosterol:cholesterol and plasma lipid levels comparing carriers of the 
ABCG8 mutation and 526 kb haplotype and individuals who are wildtype for both mutations. Values are shown as the mean ± standard deviation, with the 
number of individuals shown in brackets. N.S.: not significant, Lath:Chol: lathosterol/cholesterol ratio, TC: total cholesterol, LDL-c: low density lipoprotein cholesterol, 





The effects of the ABCG8 nonsense mutation and the 526 kb haplotype on plasma lipid 
levels were next examined.  As shown in Table 3.1, the only significant finding was a 
modest increase in total cholesterol levels in the ABCG8 nonsense mutation carriers.  The 
effect of these two variants in the ABCG5/ABCG8 region on plasma lathosterol levels 
was also assessed.  Plasma lathosterol levels have been shown to be proportional to 
whole body cholesterol synthesis.  Also shown in Table 3.1, carriers of the ABCG8 
nonsense mutation had a 12.5% decrease in plasma lathosterol (standardized to 
cholesterol and shown as a ratio of lathosterol:cholesterol) (1.33 ± 0.55) and carriers of 
the 526 kb haplotype a 45% decrease in plasma lathosterol (0.84 ± 0.38) compared to 
non-carriers (1.52 ± 0.67) (in both cases p<0.0001).  
 
Sequencing reveals a novel putative ABCG5 causal variant 
 
The 526 kb haplotype region on chromosome 2p21 encompasses both ABCG5 and 
ABCG8 and six other annotated genes (see Figure 3.6). ABCG5 and ABCG8 are 
obvious candidate genes to explain the haplotype effect. We first sequenced all 13 exons 
and adjacent intronic splice donor/acceptor site flanking sequences of these genes in four 
pairs of 526 kb haplotype carriers and non-carrier related controls. As shown in Figure 
3.6, this effort revealed a novel ABCG5 exon 10 missense mutation resulting in a coding 
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change from negatively charged aspartic acid to positively charged histidine at residue 
450 (D450H). This aspartic acid is highly conserved in vertebrates, suggesting a 
functional role that might be subverted by the histidine substitution (see Figure 3.6). 
Finally, to confirm association of the 526 kb haplotype to the ABCG5 missense mutation 
we sequenced exon 10 of ABCG5 in the remaining 48 carriers, 10 non-carrier controls,  
 
 
Figure 3.6 D450H missense mutation in exon 10 of the ABCG5 gene. The sequencing chromatograph 
showing the G to C mutation that results in a coding change from aspartic acid (D) to histidine (H) at codon 
450 in exon 10 of the ABCG5 gene. The aspartic acid is highly conserved in vertebrates. 
 
 
and 13 carriers of rs12185607/G but not the 526 kb haplotype. The ABCG5 missense 
mutation was only present in the 526 kb haplotype carriers; thus establishing complete 





We present the first implementation of a novel approach for leveraging common co-
inherited haplotypes under the local peak of a genome scan to expedite the search for the 
culprit causal variant. We analyzed a strong genetic trait, plasma plant sterol levels, in an 
extreme isolate population known to segregate a defined ABCG8 nonsense mutation on 
chromosome 2p21. Our initial GWAS analysis revealed evidence for multiple 
independent signals in the chr2p21 region. Systematic dissection of common haplotypes 
in that region using the GERMLINE software identified a single common haplotype that 
harbored a second PPS signal. Re-sequencing the exons of two candidate genes in the 
haplotype, ABCG5 and ABCG8, revealed a plausible causal genetic variant.  
 
The advantage of the IBD approach is that long shared segments bearing causal variants 
are unlikely to be shared by chance, thereby increasing their power for detection over 
traditional association mapping. Furthermore, this approach exactly identifies carriers and 
can be used to dissect multiple signals at the same locus. In the current study it was 
possible to detect a relatively rare (minor allele frequency < 1%) causal genetic variant.  
Since IBD haplotypes were constructed from SNP-chip data, this approach can 
complement a traditional association mapping method. However, the method is only 
suited to discover rare, relatively newly arisen or bottlenecked causal mutations that 
retain enough surrounding shared DNA to be detectable.  If a causal mutation arose more 
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distantly and surrounding haplotypes are too short the method will not have any mapping 
power. For example, the ABCG8 nonsense mutation was entirely described by a short 
~4kb haplotype and was not detectable by this method. The IBD approach to search for a 
causal allele affecting PPS was aided by the high degree of relatedness and founder 
effects on Kosrae that resulted in abundant, long haplotypes in our study population. 
However, recently tracks of relatedness in regions of the genome have been seen in less 
extreme founder populations (Kong, 2008), and even in apparently unrelated populations 
(Frazer, 2007).  This has motivated several groups to develop IBD methods as a means of 
mapping disease-related alleles (Gusev, 2009, Purcell, 2007, Albrechtsen, 2009). 
 
The unexpectedly large phenotypic effect of the 526 kb haplotype on PPS levels raises 
intriguing questions regarding the underlying mechanism. Given the evolutionary 
conservation of the aspartic acid residue in position 450 of ABCG5 and the 
nonconservative nature of the amino acid substitution, this variation is highly likely to be 
functional. It is unclear, however, how a missense mutation in ABCG5 elevates PPS 
levels ~100%, whereas an ABCG8 nonsense mutation, presumably yielding no full 
length protein, only elevates PPS levels ~50% (see Figure 3.3). It has been shown that 
ABCG5 functions by heterodimerization with ABCG8 (Graf, 2003).  Therefore, we 
hypothesize that the greater effect of the missense mutation is due to one of the 
following: (i) imbalanced expression of a non-functional ABCG5-mutant allele, (ii) a 
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gain-of-function dominant-negative ABCG5 mutation, or (iii) linkage disequilibrium of a 
non-functional ABCG5-mutant with other genetic variant(s) at the 526 kb haplotype. 
 
Recent well-powered meta-analyses of pooled GWAS in individuals largely of Caucasian 
ancestry found the ABCG5/ABCG8 locus associated with plasma total and LDL-
cholesterol levels (Kathiresan, 2009, Aulchenko, 2009). In the current study we found a 
modest association of the ABCG8 nonsense mutation with total cholesterol levels 
(p<0.02), but no such association for the 526 kb haplotype containing the ABCG5 
missense mutation.  This is a paradox as the greater potency of the latter mutation is 
verified both by a larger increase in PPS levels and a greater decrease in cholesterol 
synthesis as shown by more of a decrease in plasma lathosterol levels. It is possible that 
the frequency of the 526 kb haplotype is too low for an effect on plasma cholesterol to be 
seen.  It is also possible, but unlikely, that the 526 kb haplotype contains other variants 
besides the ABCG5 missense mutation that obscure effects on total and LDL cholesterol, 
while preserving affects on PPS and plasma lathosterol levels. Finally, the number of 
ABCG8 nonsense mutation carriers are relatively few in this study, especially compared 
to population based studies, and the borderline association seen with total cholesterol 
levels may be a false positive. 
 
Mutations in ABCG5 and ABCG8 are rare in the general population.  Homozygotes or 
compound heterozygotes have the disorder phytosterolemia at an estimated frequency of 
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<1:1,000,000 (there are only 40 reported cases).  It is therefore interesting that we 
observed by sampling ~3,000 adults on Kosrae a combined carrier rate of 1:8 for the two 
mutations.   The reason for such clustering is not clear, but may suggest a beneficial 
effect of these mutations or simply a chance observation owing to founder effects. 
 
In summary, we have described a novel approach to identify and dissect the effects of 
large haplotypes under the signal of a single locus detected by GWAS. This approach 
allowed identification of a novel 526 kb haplotype that modifies PPS and dissected its 











Isolated populations have a long history in genetic mapping studies of inherited disorders 
with advantages including reduced environmental, phenotypic and genotypic 
heterogeneity as compared to outbred populations (Ober, 2001 ,Angius, 2002 ,Peltonen, 
1999 ,Gulcher, 2001 ,Freimer, 1996 ,Zamel, 1996 ,Abney, 2000 ,Aulchenko, 2004 ,van 
der Walt, 2005). In particular, the reduction of genotypic heterogeneity observed in 
isolated populations due to founder effects, bottlenecks and genetic drift, may allow 
otherwise rare mutant alleles to rise to higher frequency in these populations, while at the 
same time narrowing the spectrum of candidate mutations (Ober 2001, Angius 2002). 
The increased chance for homozygosity has been a key factor in identifying mutations 
responsible for rare monogenic diseases in isolated populations (Peltonen 1999, Gulcher 
2001, Freimer 1996). Here we investigate the advantages and limitations of exploiting 
homozygosity in isolated populations for analysis of alleles effecting complex traits 
(Zamel 1996, Abney 2000, Aulchenko 2004). Genome-wide association studies (GWAS) 
performed in outbred populations have thus far identified many common variation 
contributing to complex diseases (Manolio 2008). One limitation in these studies is that 
rare variants that are not in linkage disequilibrium with the common variants assayed are 
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usually not detected (Bodmer, 2008). However, when the populations analyzed in a 
GWAS have a substantial number of individuals that share a recent common ancestor, not 
only common variants (Lowe, 2009, Wang, 2009), but sometimes also rare variants 
affecting complex disorders can be identified (Sabatti, 2009, Pollin, 2008, Kallio, 2009). 
 
Genetic analysis of isolated populations pose unique challenges for traditional GWAS 
methods that have been mainly focused on outbred populations (Bourgain, 2005). The 
crux of the difference is that in isolated populations the likelihood of any two individuals 
in the population to be related is not negligible. The resulting direct and cryptic 
relatedness confounds assumptions of independence between genotypes of different 
individuals, as well as between their heritable phenotypes. Isolated populations therefore 
contain a large amount of cross-individual correlations which pose problems for most 
mapping methods. Further, consanguinity may be present so that two alleles in a random 
individual may also be correlated. The hidden correlation in the data can cause an 
overdispersion of the naïve test scores for association and consequently, lead to false 
positive associations. Hence, the major challenge for performing GWAS in isolated 
populations is to account for this non-random intra- and inter-individual correlation. 
 
While standard association tests assume independence of genotypes and phenotypes 
across samples, several specialized approaches for association do account for underlying 
relatedness expected in isolated populations. In this work, we set out to select and 
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evaluate these different methods for maping complex traits in an isolated founder 
population. Some of these methods rely on knowledge of the underlying family structure 
in the population. These approaches overcome the confounding effects of non-random 
correlation via deconstruction of the population into family units and analysis of 
association independently within each unit (within family variance) (Lange, 2004 
,Abecasis, 2000 ,Almasy, 1998). Some of these “family-based” methods have been 
extended by adding the variance between families to the within family variance (Devlin, 
1999, Purcell, 2007, Abecasis, 2001,Abecasis, 2002 ,Won, 2009). A different type of 
“population-based” approach does not utilize prior knowledge of family structure, but 
rather explicitly models the relatedness between all pairs of individuals based on their 
genotypes, and incorporates this variance into a mixed model for association (Yu, 2006 
,Abecasis, 2001 ,Kang, 2008, Aulchenko, 2007, Amin, 2007, Kang, 2010, Zhang, 2010). 
Such models have recently been extended to genome-scale human studies and have been 
shown to effectively control for population structure (Zhang, 2010, Kang, 2010). Here 






Figure 4.1:  Schema of the sibship- and kinship matrix- based approaches to association studies in related 
cohorts. (A) The extended Kosrae pedigree is broken into sibships without parents (indicated by the dotted 
gray circle). Parent-child or cousin relationships may exist between different sibships. Tests of association 
may be performed within sibships (gray arrows) and between sibships (black arrows). (B) A kinship matrix 
of all pairs of the same individual. 
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We compared the performance of the four representative methods that account differently 
for relatedness while testing for genome-wide association: (i) focusing on allele 
transmission to offspring within families (Lange, 2004), (ii) measuring association within 
as well as between families (Devlin, 1999 ,Purcell, 2007, Won, 2009), and (iii) capturing 
the relatedness between all individuals in the population to construct a mixed model to 
test for association (Kang, 2010). Our simulations showed the mixed model method to 
have increased statistical power to detect association, offering a 1.8- to 2-fold 






Five representative programs for performing association in the context of relatedness 
(FBAT, FBAT+Wald, PLINK/QFAM-total, EMMAX and SOLAR – see description 
below) were assessed for speed and maximum memory allocation to determine their 
suitability for a genome-scale association analysis across thousands of individuals. The 
average computation time for association per marker for each program is given in Table 




 FBAT FBAT+Wald PLINK/QFAM-total EMMAX SOLAR 
Speed 
(sec/SNP) 
0.013 0.021 0.057 0.039 8.74 
Memory 
(MB ram) 
1,660 1,660 760 790 3,200 
Table 4.1:  Computation time (average computation time per second per SNP) and maximum memory 





seconds/SNP, with FBAT performing > 2-fold faster than the other three methods, 
compared to the SOLAR method which was > 100-fold slower. The slow speed of the 
SOLAR method prohibited its further inclusion in the study. The maximum virtual 
memory allocation required by the remaining four methods did not exceed 1.7GB of 
RAM during the runtime of each program. 
 
Strategy for accuracy and efficacy comparison on known-answer data 
 
We evaluated the performance of different approaches to genome-wide association in the 
context of relatedness by comparing representative tools for each approach. The family-
based association test (FBAT) is a method that considers allele transmission to offspring 
within families (Lange, 2004). The FBAT group has recently suggested an extension of 
their method that combines the within-family FBAT score with a rank-based, between-
family score, derived from a Wald test of the whole cohort, that is robust to 
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overdispersion, into one single test statistic (FBAT+Wald), which we also tested (Won, 
2009). Plink family-based association test for quantitative traits, within- and between-
mode (PLINK/QFAM-total), uses a linear regression-based between/within family 
approach similar to a model described previously (Abecasis, 2000, Fulker, 1999). In the 
PLINK/QFAM-total framework, confounding effects of family structure are controlled 
by independent within- and between-family permutation strategies for estimating exact 
significance levels, where the empirical within-and between family permuted p-values 
are combined to a single score.  We corrected for any residual overinflation of the test 
statistic by standard genomic control adjustment (Devlin, 1999, Purcell, 2007). Finally, 
efficient mixed model association expedited (EMMAX) is a method that first uses high-
density genotypes to empirically estimate levels of relatedness between every pair of 
individuals, which are captured in a kinship matrix. The kinship matrix is then 
incorporated into a linear mixed model to adjust for correlation in the phenotypic 
distribution during association mapping (Kang, 2010). We used all four methods to 
perform genome-wide association analysis in a highly related, population-based cohort 
from the Island of Kosrae, Micronesia, that is comparable in size (n = 2,906) to published 
single study case/control cohorts.  
 
In order to assess the empirical power for each association method, we considered data 
for over 350,000 SNPs, with a minor allele frequency greater than 0.01, genotyped on an 
Affymetrix 500K platform in the Kosrae samples. We repeatedly analyzed association of 
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these SNPs to a null, moderately heritable (h
2
 = 0.42 on Kosrae) phenotype, body mass 
index (BMI), which we modified afresh multiple times. Each modified phenotype 
included a simulated genotype/phenotype association explaining 2% of the phenotypic 
variance to a different random SNP, additively combined to the true trait value. This 
effect size was chosen to echo milder effects detected and detectable in larger-sample 
studies that are now available. These datasets were constructed by selecting 1,000 SNPs 
randomly across the genome (770 common SNPs after filtering, see methods), where 
each phenotype was altered to reflect association to a different SNP in the random subset. 
In total, 770 genome-scale datasets containing modified SNP-phenotype association were 
generated and analyzed by all four methods.  
 
Following extensive pedigree construction based on genetic and oral information, more 
than 90% of the genotyped individuals on Kosrae form a single extended pedigree 
spanning 5+ generations and containing numerous consanguineous offspring and multiple 
marriage loops (Lowe, 2009). To the best of our knowledge, large pedigrees with such 
complexity cannot be handled whole by methods that have a within-family component. 
Therefore, we broke our pedigree into smaller units of sibships-without-parents for the 
purposes of method comparison. This resulted in 586 sibships consisting of two or more 
individuals who share a mother and father (Figure 1A). Any genotyped parents are 
considered only in the context of the parents‟ sibship. Of the individuals not included in 
any sibship (n = 612), a subset was identified in which any two members of the subset 
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were related to the degree of first cousins or less, as determined by genome-wide 
identity-by-descent sharing, resulting in 240 additional “sibships” of size 1. To fairly 
compare FBAT and PLINK/QFAM-total to EMMAX and FBAT+Wald, we first 
analyzed only sibship individuals. However, to also quantify the benefits of using the 
entire dataset, we repeated the analysis examining the entire cohort with EMMAX and 
the sibships for the FBAT and entire cohort for the Wald components of the FBAT+Wald 
method. 
 
Empirical power results 
 
The empirical power for each method was recorded in two ways: the reported (i) genome-
wide rank (Figure 4.2A) and (ii) p-value (Figure 4.2B) of the ground-truth SNP 
according to each method across repeated simulation iterations. While these criteria are 
equivalent when reported p-values are uniformly distributed (as required by the definition 
of a p-value), inclusion of both criteria facilitates evaluation of potential bias in such 
distributions. Comparison of the within-family only (FBAT) vs. combined within- and 
between-family (PLINK/QFAM-total and FBAT+Wald) vs. mixed model (EMMAX) 
tests demonstrated that the greatest power, as measured by rank order of the true effect, 
was obtained by the use of the mixed model method. EMMAX had 88% power to rank 
the true SNP in the top 10 genome-wide, a 1.7-, 2- and 2.1-fold improvement over 
PLINK/QFAM-total, FBAT and FBAT+Wald, respectively (Figure 4.2A). In addition, 
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56% of truly associated SNPs achieved genome-wide significance (gws) for the mixed 
model method compared to < 16% for the other methods (Figure 4.2B – see discussion). 
Although, the inclusion of the entire cohort (an additional ~300 individuals that did not 
fall into sibships) in the FBAT+Wald method increased the number of truly associated 
SNPs that achieved gws to 21%, this was less than half of the gws SNPs EMMAX 
detected.  The improvement in power was also observed in comparison of the 
PLINK/QFAM-total naïve test scores (i.e. not adjusted for genomic control) with 
EMMAX, indicating that the dampening effect of the lambda correction does not account 
for the total power difference between the two methods (Figure 4.2B). Finally, the 
EMMAX analysis of the entire cohort showed a further 1.2-fold increase in power for the 
top 10 ranked ground truth SNPs, with an additional 10% of SNPs surpassing genome-





Figure 4.2:  Empirical estimation of power of association for four representative association methods for 
related cohorts. (A) The aggregate rank of the ground truth SNP across 770 simulated dataset for 
association performed with FBAT, FBAT+Wald, PLINK/QFAM-total + genomic control and EMMAX 
with sibship structured (n = 2,007) and FBAT+Wald and EMMAX with all individuals (n = 2,317). (B) The 
aggregate p-value‟s of the ground truth SNP for association performed with FBAT, FBAT+Wald, 
Plink/QFAM-total + genomic control, Plink/QFAM-total without genomic control and EMMAX with 






To determine which association method would be best powered to analyze a highly 
related isolate population, we compared four methods utilizing different approaches for 
capturing underlying population structure. One of the methods measured variance within 
family units and three of the methods added the variance between families using different 
strategies to control for the over-inflation of the naïve score that resulted from the sample 
structure. Two of the approaches uniformly rescaled the markers by adding a rank-based 
p-value to a score or adjusting the score for overinflation by genomic control. These 
approaches reduce false positives, but also lead to decreased power for true positives. The 
mixed-model approach modified the test statistic in a marker specific way, which in turn 
changed the ranks of associated results, so that false positives are reduced, but true 
positives did not change. In our evaluation of four representative methods for mapping 
disease alleles in highly related isolated populations, we found that the mixed-model 
method significantly outperformed the other three methods. The power difference was 
indeed in part due to the over-conservative uniform adjustments, but they did not account 
for all the power difference between the two methods. The kinship matrix incorporated in 
the mixed-model likely captured more between-family variance than the other methods. 
Further, since the mixed-model method was not restricted to families, an analysis across 




Handling hidden and direct relatedness in the context of a mixed-model has both 
theoretical and practical advantages over other approaches for association testing in 
closely-knit, isolated cohorts. Theoretically, it handles relatives distant and close, 
demographic trends and complex pedigrees (variation both within and between families 
is utilized) and the test statistic produced is uniformly distributed, with no artificial 
overdispersion of the p-value. Practically, the ability to include all samples in the analysis 
gave a > 2-fold boost in power and our empirical results support the use of mixed-models 
for association in populations such as our Kosrae samples.  
 
It is worthwhile reviewing our work in the context of recent ideas and results in 
association analysis. Specifically, the emerging picture is that despite comprehensive 
scans of association with common SNPs of multiple complex phenotypes, only a limited 
fraction of their heritable component has been identified (Frazer, 2009, Hindorff, 2009, 
Frazer, 2009, Hindorff, 2009, Frazer, 2009, Hindorff, 2009). Expanding the search for 
associated alleles to variants that are rare in the general population provides another piece 
of this heritable component, with multiple gene sequencing studies implicating such 
variants with moderate to high penetrance (Fearnhead, 2004, Cohen, 2004, Kotowski, 
2006, Romeo, 2007, Marini, 2008, Fearnhead, 2004, Cohen, 2004, Kotowski, 2006 
,Romeo, 2007, Marini, 2008, Fearnhead, 2004, Cohen, 2004, Kotowski, 2006, Romeo, 
2007, Marini, 2008). Our experiences in association testing in an isolated population can 
serve as a model for other studies of similar cohorts. Methodologically, mixed-models 
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optimally extract association information from such samples. As GWAS cohorts increase 
in size to the 6-digit range, and inclusion of somewhat related individuals becomes a 
practical modus operandi, results in this work are expected to become relevant to a wide 









It has been shown that the limited genetic diversity and reduced allelic heterogeneity 
observed in isolated founder populations facilitates discovery of loci contributing to both 
rare monogenic traits and complex disease (Peltonen, 2000, Gulcher, 2001, Heutink, 
2002). A strong founder effect, severe isolation and substantial inbreeding have 
dramatically reduced genetic diversity in the indigenous population form the island of 
Kosrae, Federated States of Micronesia(Lowe, 2009, Bonnen, 2006). The Islanders also 
exhibit a high prevalence of diabetes, obesity and other metabolic disorders (Shmulewitz, 
2001). Here we present a genome-wide association study of 30 traits pertaining to 
metabolic disorder and electrocardiographic measures on the island.  
 
Mapping in large, highly related, multi-generational cohorts is analytically challenging, 
as extensive relatedness between subjects violates assumptions of independence upon 
which traditional association tests are based. However, rigorous power analysis of several 
specialized methods designed to accommodate complex familial relationships revealed 
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that a mixed model approach optimally extracted association information from such 
samples, demonstrating that population isolates have similar power to non-isolate 
populations (see Chapter 4).   Therefore, we used the mixed model method for genome 
scans in 2,906 related individuals from the Island of Kosrae, Federated States of 
Micronesia, who were previously genotyped for over 350,000 SNPs. 
 
 We re-analyzed data for 17 phenotypes previously studied in this cohort (Lowe, 2009, 
Smith, 2009), along with 8 additional phenotypes. As positive controls, we observed nine 
genome-wide significant associations with known loci of measured levels of plasma 
cholesterol, high density lipoprotein, low density lipoprotein, triglycerides, thyroid 
stimulating hormone, homocysteine, C-reactive protein and uric acid, with only one 
detected in previous analysis of the same traits(Lowe, 2009). In addition, we refined the 
broad signal peak for uric acid levels (chr11:59.1-65.3MB) by analysis of identity-by-
descent (IBD) shared genetic segments and dissected the full set of long-range shared 
haplotypes in this region. We identified a single 3% carrier frequency haplotype that 
accounted for the entire signal in that region, and replicated one of the two previously 
known signals, refining that signal by a factor of four. Finally, we show a region of novel 







We performed a population-based screen of native Kosraens over three separate visits to 
the Island in 1994, 2001 and 2003 (Shmulewitz, 2006, Shmulewitz, 2001, Lowe, 2009) – 
see Table 5.1. Self –reported family relationships were recorded for use in constructing 
pedigrees and blood was collected for DNA extraction and genotyping. Genetic accuracy 
of the Kosrae pedigree was assessed using pairwise identity-by-descent (IBD) estimates 
generated in PLINK (Purcell, 2007) (see Materials and Methods).The total number of 
unique individuals from the three screens that were successfully genotyped was 2,906, 
representing >75% of the adult population on the Island.   
 
 N total N unique %Males/Females Mean age Median age Age range 
1994 1,935 903 49.6/50.4 43 39 20-86 
2001 1,968 889 40.8/59.2 28 24 16-80 
2003 84 33 51.5/48.5 24 22 16-53 
Multiple 
exams 
- 1,081 35.3/64.7 47 46 17-89 
Total 3,987 2,906 41.6/58.4 40 38 16-89 
Table 5.1 Study participants successfully genotyped for the Affymetrix 500k assay. Screenings tood 
place in 1994,2001 and 2003. For each screen, the total and unique number of individuals examined is 
shown, as some participants were examined in multiple screens. For subjects examined more than once, age 




Phenotypes pertaining to Metabolic Syndrome and Electrocardiographic measures 
 
A rich, 30-strong phenotypic dataset was collected that included multiple 
anthropomorphic and Metabolic Syndrome related phenotypes: height(HGT), weight 
(WGT), waist circumference (WST), bodpod percentage fat assessment (PCF), body 
mass index (BMI), leptin hormone levels (LEP), diastolic blood pressure (DBP), systolic 
blood pressure (SBP), total cholesterol levels (TC), low-density liprotein cholesterol 
levels (LDL), high-density lipoprotein cholesterol levels (HDL), triglyceride levels (TG), 
campesterol levels (CMP), sitosterol levels (SIT), lathosterol levels (LAT) (CMP, SIT 
and LAT are collectively called plasma plant sterols (PPS)), fasting plasma glucose 
(FPG), haemoglobin A1C levels (HBA1C) and insulin sensitivity (INS).  In addition, a 
number of metabolic hormone and inflammation markers were collected: C-reactive 
protein (CRP), thyroid stimulating hormone (TSH), homocysteine (HOMO), folic acid 
(FLT), uric acid (URT) and creatinine levels, from which glomular filtration rates were 
derived (GFR). Finally, a set of electrocardiographic measurements were taken on the 
Island and a number of electrocardiographic conductance metrics were derived: QRS 
duration (QRS), PR interval (PR), QT interval (QT), resting heart rate (RR), Sokolow-
Lyon voltage (SLV) and Cornell voltage (CLV).  The heritability of each trait was 
calculated in two ways: under a classical polygenic model using nuclear families in 
SOLAR (Almasy, 1998) and by calculating the fraction of phenotypic variance explained 



























g,a 0.425 0.503 
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g,a,b 0.245 0.346 







































g,a 0.160 0.206 









































g,a 0.430 0.360 









g,a 0.473 0.521 









g,a 0.414 0.485 









g,a 0.196 0.251 



















g,a 0.204 0.223 









g,a,b 0.243 0.298 









g,a,b 0.289 0.346 
Table 5.2 Phenotype characteristics. For each trait; the mean±standard deviation of the raw phenotype, and the number of all phenotyped individuals (All), the 
mean±standard deviation of the raw phenotype, and the number of male phenotyped individuals (Male), the mean±standard deviation of the raw phenotype, and 
the number of female phenotyped individuals (Female), any covariates that were adjusted for (Covariates), heritabilites as calculated using a polygenic model in 
SOLAR (h
2




Trait: the trait (units of measurement) 
2
 Mean±standard deviation, number of phenotyped samples used in the analysis 
3
Covariates; g=gender, a=age, b=bmi 
4
For the 1994 screen, LDL and HDL quantification was not possible due to the lack of an adequate centrifuge on the island and the inability to ship serum 
overnight at 4 C.  As substitutes, the major apolipoproteins of LDL and HDL (APOB (mg/dL), and APOA-I (mg/dL), respectively) were measured using a 
standard double antibody immunoassay.  Both APOB and APOA-I are highly correlated with their respective cholesterol fractions, making them excellent 
surrogates. For 1,081 individuals who were screened in both 1994 and 2001, the average of their Z-scores for the both measurements was used. 
5
The distribution of Lipoprotein(a) levels was tri-modal, and raw values with no normalization were used in the association mapping 
6
Plasma plant sterols (Campesterol, Sitosterol and Lathosterol) are give as a ratio with Total Cholesterol 
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designated “psuedoheritability” since the estimated pairwise relatedness does not 
correspond exactly to the kinship coefficients. Nonetheless, the EMMAX heritability 
estimates are concordant with the heritability estimates from the nuclear families (r
2
>0.9). 
The details of the phenotypes, including population means and covariate adjustments 
heritability estimates for the metabolic traits, are given in Table 5.2 Electrocardiographic 
measures are also given (Lowe, 2009, Smith, 2009). 
 
Results from the genome-wide association analysis of 30 metabolic and 
electrocardiographic traits.  
 
Based on our observations from the simulated data (see Chapter 4), we selected the 
mixed model method as the most powerful method for analyzing our study population. 
We first built a kinship matrix of pairwise identity-by-state metrics based on high-density 
markers for the entire pedigree, which was then incorporated into the mixed model for 
association mapping (Kang, 2010). We had previously published the results of the 
genome-wide association analysis of 17 of these traits using the PLINK/QFAM-total 
framework (Lowe, 2009, Smith, 2009). Here, we re-analyzed data for these 17 published 
phenotypes using the EMMAX framework, along with another 13 previously unreported 





Symbol Trait #SNPs λ 
TC Total cholesterol 354,880 1.0044 
LDL Low density lipoprotein cholesterol 354,901 0.9785 
HDL High density lipoprotein cholesterol 354,005 0.9714 
TG Triglycerides 354,250 1.0066 
CMP
1
 Campesterol:Cholesterol 323,674 1.0103 
SIT
1
 Sitosterol:Cholesterol 323,437 1.0029 
LAT
1
 Lathosterol:Cholesterol 323,391 1.0034 
CRP C-reactive protein 329,883 1.0220 
GFR Glomular filtration rate 329,414 0.9894 
URT Uric acid 323,483 1.0064 
FLT Folic acid 323,869 0.9945 
HOMO Homocysteine 323,775 1.0123 
TSH Thyroid stimulating hormone 354,558 1.0170 
HGT Height 354,661 0.9756 
WT Weight 354,213 0.9690 
WST Waist circumference 354,290 0.9876 
BMI Body mass index 352,213 0.9599 
PCF Percent body fat 323,923 0.9947 
LEP Leptin hormone levels 323,797 0.9872 
FBS Fasting  blood sugar 348,036 1.0135 
HBA1C Haemoglobin A1C 324,031 1.0122 
INS Insulin sensitivity 340,724 0.9975 
SBP Systolic blood pressure 353,640 1.0292 
DBP Diastolic blood pressure 353,640 1.0088 
RRD Resting rate interval 340,312 1.0092 
PRD PR interval 346,566 1.0188 
QRS QRS interval 346,710 1.0159 
CLV Cornell voltage 346,710 1.0082 
SLV Sokolow-Lyon voltage 346,710 1.0160 
    
Table 5.3 Number of SNP’s tested for each trait and estimate of p-value score inflation. For each trait; 
the number of >0.01 MAF SNP's per phenotype (#SNP's) and genomic control correction factor (λmedian) 
from the p-value distribution from the EMMAX association mapping (Devlin, 1999). 
1
The λ for the three plasma plant sterol traits was calculated after the removal of the SNP‟s comprising the 
broad peak around the top SNP (Chr2:36-47MB), see chapter 3 for details. 
 
We observe minimal score inflation using the EMMAX method where the inflation factor 
 is estimated to be in the range from 1.03 to 0.96 for all traits (see Table 5.3). This is in 
contrast with previously reported  values that are significantly greater than 1 for a subset 
of the traits analyzed using PLINK/QFAM -total ( range: 2.05 – 1.10)(Lowe, 2009). We 
noted that genome-wide analysis with =1.1 inflation of p-values results in a 4.8-fold 
83 
 
increase in the expected number of false-positive results attaining genome-wide 
significance, with practical implication for the feasibility of follow-upTable 5.4 provides 
the top SNP per region emerging genome- and study-wide significant from the EMMAX 
analysis of all 30 traits. We determined a genome-wide significance threshold based on 
~310K effective independent tests (~350k-320k actual tests) to be 1.6x10
-7
 (see 







 Top SNP A1
3 





      β
5 
s.e.
6    
TC 2,753          
  19:45.4 rs4420638 G/A 0.182 0.274 0.033 2.42 1.47x10
-17
 APOE 
LDL 2,775          
  19:45.4 rs4420638(+1) G/A 0.182 0.316 0.033 3.24 2.57x10
-23
 APOE 
  5:74.7 rs3846663 T/C 0.197 0.210 0.029 1.93 8.81x10
-7
 HMGCR 
HDL 2,774          
  16:57.0 rs1800775 A/C 0.394 0.183 0.026 1.82 7.03x10
-9
 CETP 
  19:45.4 rs4420638 G/A 0.182 -0.198 0.033 1.16 6.30x10
-7
 APOE 
TG 2,754          
  11:116.7 rs7396835(+6) T/C 0.372 0.214 0.026 2.36 2.42x10
-12
 APOA5/APOCIII 
CRP 1,872          
  19:45.4 rs4420638 G/A 0.182 -0.318 0.041 3.05 6.16x10
-13
 APOE 
  1:159.7 rs3093077(+4) C/A 0.247 0.245 0.037 2.25 7.10x10
-9
 CRP 
HOMO 1,870          
  11:89.3 rs1836883 T/C 0.321 0.210 0.036 1.75 1.29x10
-8
 NOX4 
TSH 1,858          
  9:100.5 rs1877431(+19) A/G 0.224 -0.299 0.037 3.46 6.32x10
-14
 FOXE1 
HGT 2,364          
  17:43.0 rs17629022 C/T 0.064 0.481 0.058 2.83 2.00x10
-8
 GFAP 
URT 1,861          





QT 1,432          
  21:34.7 rs2070359(+1) A/C 0.373 -0.226 0.032 2.35 5.17x10
-9
 KCNE1 
HBA1C 1,860          
  16:89.0 rs2968474 A/C 0.224 -0.309 0.021 3.05 7.20x10
-9
 CBFA2T3 
PPS 2.034          






Table 5.4 Genome- and study-wide significant SNPs from the analysis of 30 traits.This table lists the top SNP in a genetic region for the association of 25 
traits pertaining to metabolic syndrome and electrocardiographic conductance that surpasses genome-wide significance (p≤ 1.6x10
-7
). SNP’s that also surpassed 
study-wide significance (p≤ 6.4x10
-9
) are indicated in italics. 
1
 N; the number of phenotyped individuals for the trait 
2
POS(MB): chromosomal physical position in megabases; Genome Reference Consortium build 37 (GRCh37) 
3
A1; the minor allele 
4
A2: the major allele 
5
β; the effect size (linear mixed model regression coefficient) 
6
s.e.; the standard error of the effect size 
7
%var; the percent variance explained (oneway ANOVA) 
8
 Candidate genes in the region of the top SNP 
9





Observation of positive controls in the Kosare dataset 
 
As positive controls, we observed associations to ten genomic regions for ten traits 
exceeding our genome-wide significance threshold. Top SNPs are in or near to known 
loci for plasma cholesterol (APOE; rs4420638, p ≤ 1.47x10
-17
), high density lipoprotein 
(CETP; rs1800775, p ≤ 7.03x10
-9
), low density lipoprotein (APOE; rs4420638, p ≤ 
1.47x10
-23
), triglycerides (APOC3/A5; rs7396835, p ≤ 2.42x10
-12
), thyroid stimulating 
hormone (FOXE1; rs1877431, p ≤ 6.32x10
-14
), homocysteine (NOX4; rs1836883, 
p≤1.3x10
-8
), C-reactive protein (APOE; rs4420638, p ≤ 6.16x10
-13
 and CRP; rs3093077, 
p ≤ 7.10x10
-9
), QT interval (KCNE1; rs2070359, p ≤ 5.2x10
-9
) and the plasma plant 
sterols (ABCG5/ABCG8; rs12185607, 3.21×10
-31
) (Kathiresan, 2009, Kathiresan, 2008, 
Elliott, 2009, Willer, 2008, Sandhu, 2008, Gudmundsson, 2009, Pare, 2009). Nine of 
these regions are shown in detail in Figure 5.1A (for details regarding the plasma plant 
sterol region, see Chapter 2). Furthermore, six of these signal peaks surpassed our study-
wide significance threshold of 6.4x10
-9 
(see Material and Methods). Only one of these 
positive controls had been detected at genome-wide significance in the previous analysis 
of the same traits: triglycerides (APOC3/A5; rs7396835, p ≤ 1.2x10
-9
) (Lowe, 2009). In 
addition we observed two other known positive controls significant at FDR <0.3: low 
density lipoproteins (HMGCR; rs3846663, p ≤ 8.77x10
-7
) and high density lipoprotein 
(APOE; rs4420638, p ≤ 6.33x10
-7
)(Kathiresan, 2009, Aulchenko, 2009). 
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Novel findings from the Kosrae association mapping 
 
As novel findings, we observed three interesting genome-wide significant signals, one 
strong signal for uric acid levels that resides >500kb upstream of two independent known 
associations (rs2186571, p<1.8x10
-34
), and signals for height and HBA1C which 





, respectively; see Figures 5.1B and 5.1C).  
The novel SNP rs17629022 for height has a minor allele frequency of 0.06 and a strong 
effect size of 0.48 standard deviations per allele (for normalize z-scores, μ=0, σ=±1). This 
corresponds to an average 1.28” (95% confidence intervals: 0.97”-1.66”) and 4.23” (95% 
confidence interval: 2.48”-5.97”) average increase in height in carriers (n=271) and 
minor allele homozygotes (n=13), respectively, compared to major allele homozygotes. 
The SNP resides on chromosome 17q21 in a gene rich region containing GAP, CCDC103 
and FAM187A.  
The novel SNP rs2968474 for HBA1C has a minor allele frequency of 0.224 and a strong 
effect size of -0.309 standard deviations per allele. In work by my collegue, Sasha Gusev, 
the signal for this SNP was fine mapped to a 200kb, 11 SNP haplotype in the region 
(p<1.66x10
-23
), where the HBA1C haplotype carriers (n=284) and homozygotes (n=8) 
have decreased HBA1C levels, 5.00%±0.57% and 4.13%±0.51%, respectively, compared 
to non-carriers (n=1,282), 5.33%±0.53%. Further, low pass sequencing in the region 




Figure 5.1 Eleven regions of genome-wide significant associations. (A) We observe nine genome-wide 
significant associations to known loci for plasma cholesterol, high density lipoprotein, low density 
lipoprotein, triglycerides, thyroid stimulating hormone, homocysteine, C-reactive protein and QT interval 
(the tenth positive control, ABCG8/G5 region for PPS is described in Chapter 2). (B) Region of novel 
association for height and haemoglobin A1C. The y-axis show’s –log10p-value (LOD) and the x-axis shows 
the chromosomal physical position in megabases. The maroon square represents the location of the top 




the haplotype and structural variation in carriers. This work is currently under preparation 
for publication (pers. comm. Sasha Gusev).  Analysis of the uric acid trait revealed a 
broad peak in the genome scan on chromosome 11q13.1 (59.2-65.3 MB) containing 54 
SNPs that surpassed the study-wide significance threshold (Figure 5.3C). The top SNP, 
rs2186571, represents a novel association to uric acid. Further, the very low p-value of 
the top SNP p<1.8x10
-34
, signifies an effective internal replication of the signal, since, for 
an effect this strong, a genome-wide significant signal would be observed in any 
randomly partitioned half of the study population. rs2186571/A has a minor allele 
frequency of 0.028 and a strong effect size of -1.14 standard deviations per allele, 
accounting for ~10% of uric acid level variance on Kosrae, where carriers of 
rs2186571/A have a mean uric acid level of 3.6 mg/dL compared to the major allele 
homozygotes level of 5.5 mg/dL.  However, rs2186571 resides ~500kb upstream of two 
variants on chromosome 11q13.1 recently found to be associated with uric acid levels 
(Kolz, 2009). To determine whether the strong uric acid signal represented a novel 
observation or might tag either of the previously observed signals, we performed a 
haplotype-based fine-mapping of the signal region and conditional analysis.  
 
Fine mapping the interval of uric acid association 
 
Haplotype mapping has been previously described in Chapter 2. Briefly, common shared 
long-range haplotypes were detected via pair-wise IBD genetic segment matching 
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between all individuals in the pedigree using the GERMLINE software (Gusev, 2009). 
The IBD segments were at least 3cM in length and allowed for up to 1% mismatching 
due to genotyping error.  IBD segments were then clustered to groups of similar 
haplotypes, with >500kb overlapping sequence and sharing >99% sequence identity, as 
described in detail previously (Kenny, 2009). Clusters of shared haplotypes were then 
independently mapped to uric acid levels which identified a single strong mapping 
cluster, where the specific sharing boundaries of the haplotype  mapped to a ~2MB sub-
region (chr11:63.7-65.5) of the uric acid GWAS signal peak (see Figure5.2(A)). This 
"uric acid haplotype" (rs4980499 to rs1074156) is unique to a group of 96 individuals 
(carrier frequency 0.03), is strongly associated to uric acid (p<9.07x10
-46
), and has an 
effect size of -2.12 standard deviations per allele (accounting for ~20% of uric acid level 
variance on Kosrae; 95% confidence intervals 16.8%-21.6%).  Conditioning the uric acid 
levels for the uric acid haplotype effect abolishes signal at the rs218571 SNP (p<0.83), 
whereas, a significant signal remains (p<2.1x10
-5
) at the uric acid haplotype when the 
levels are adjusted for the effect of rs218571 (see Table 5.5). Genome-wide scan of 
haplotype conditioned uric acid levels reveals no remaining genome-wide significant 
signals (see Figure 5.2(B)). Therefore, the uric acid haplotype likely captures the full 
signal tagged by the top GWAS SNP. 
 
We next determined whether the uric acid haplotype represented a novel variant or a 
refinement of one or both loci that had previously shown uric acid variants, rs17300741 
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and rs505802. The two known variants reside in/near organic ion transporter 4 (OAT4) 
and urate transporter 1 (URAT1), respectively, which are known candidate genes for renal 
urate anion exchange and are thought to regulate blood uric acid levels (Taniguchi, 2008, 
Ekaratanawong, 2004).   Neither variant was directly assayed in the Kosrae genotype 
panel. However, two assayed variants on the 500k Affymetrix chip, rs12362644 and 
rs10897518 that flank rs17300741 and rs505802, respectively, were observed to be in 
complete linkage disequilibrium (r
2
=1) with each variant in all HapMap Asian panels 
(CHB, CHD, JPT, GIH). We therefore concluded that rs12362644 and rs10897518 
genotyped on Kosrae would be strong tags for the unobserved rs17300741 and rs505802 
variants, respectively. Indeed, signals for association were observed for rs12362644 (p < 
8.16x10
-5
) and rs10897518 (p < 3.41x10
-17
), the latter being study-wide significant. 
  
Analysis of the uric acid haplotype conditioned on rs12362644 and rs10897518 abolished 
the signal at these two variants (p<0.41 and p<0.93, respectively). However, the strong 
signal at the uric acid haplotype persisted (p< 8.48x10
-23
). Conversely, when uric acid 
levels are conditioned on the uric acid haplotype, moderate signal for rs12362644 
(tagging rs17300741) remained 2.66x10
-3
; however, signal at rs1087518 (tagging 
rs505802) was abolished (p<0.94) (see Table 5.5), indicating that, while there is some 
correlation between rs12362644 and the uric acid haplotype, the haplotype effect is not 
explained by the effect of rs12362644.  Instead, this effect is the result of the variant 




Figure 5.2 Conditioning on the URT haplotype. (A) Chromosome 11q13 region of association to uric 
acid levels before and after conditioning uric acid levels on the uric acid haplotype. (B) QQ plot showing 





Moreover, comparing the 0.06 frequency of rs1087518 on Kosrae to the lower 0.015 
frequency of the uric acid haplotype indicated a refinement of the signal by a factor of 4, 
dramatically reducing the sequence and sample search space for pinpointing the 
underlying causal variant. 
 
Comparison of effect sizes for known associated loci 
 
We observe that for common variants that are polymorphic in Kosrae, this cohort often 
achieves significant association, with significantly stronger statistical support than its 
sample size would suggest. A good example for that is the LDL phenotype, where ~2,800 
phenotyped islanders are sufficient  to detect positive controls signals – known 
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Table 5.5 Conditional analysis. Conditional analysis of the URT haplotype, rs12362644 (tagging 
rs17300741) and rs10897508 (tagging rs505802) at the uric acid locus on chromosome 11q13.1 
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, respectively. We extrapolated from reports in cohorts from 
European populations (Kathiresan, 2008,  Aulchenko, 2009) that >10000 samples are 
needed to expose these associations at this significance level. Comparing the association 
regression coefficients () shows a larger increase on the normalized phenotype in 
Kosrae. 
 
To more formally examine the genetics of common traits on Kosrae as compared to 
outbred populations, we assessed the effect sizes of known loci observed in our study. 
Specifically, we identified 53 established associations in large, mainly Caucasian studies 
across seven traits (BMI, CRP, HDL, HGT, LDL, TG and URT), where the associations 
had sufficiently high effect size and/or allele frequency to be detectable at nominal 
significance in the ~3,000-strong Kosrae study (see Table 5.6)
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Trait SNP Gene/Region Allele
1
 Freq Beta P-value On 500K?
2
 Freq Beta P-value Study
3
 
BMI rs9939609 FTO A 0.45 0.1 2.00E-20 same 0.12 0.13 3.00E-02 Frayling(2007) 
BMI rs17782313 MC4R C 0.28 0.05 2.80E-15 same 0.08 -0.04 5.70E-01 Loos(2008) 
CRP rs4420638 APOE G 0.18 -0.21 5.00E-27 same 0.21 -0.32 6.50E-13 Ridker(2008) 
CRP rs7310409 HNF1A A 0.39 -0.15 6.80E-17 rs2393791 0.44 -0.139 2.84E-04 Ridker(2008) 
CRP rs7553007 CRP A 0.33 -0.2 1.10E-26 same 0.38 0.111 3.90E-03 Ridker(2008) 
CRP rs4129267 IL6R A 0.4 -0.1 2.00E-08 rs4537545 0.36 -0.097 8.56E-03 Ridker(2008) 
HDL rs1800775 CETP C 0.43 -0.18 1.00E-73 same 0.58 -0.169 7.58E-09 Kathiresan (2008) 
HDL rs328 LPL G 0.13 0.17 9.00E-23 rs10503669 0.98 0.247 1.03E-02 Kathiresan (2008) 
HDL rs7395662 MADD-FOLH1 G 0.61 -0.073 6.00E-11 same 0.43 -0.05 1.21E-01 Aulchenko(2009) 
HDL rs4939883 LIPG A 0.83 0.07 2.40E-07 same 0.64 0.084 2.16E-01 Aulchenko(2009) 
HDL rs2271293 CTCF-PRMT8 G 0.87 -0.129 8.30E-16 same 0.6 -0.06 2.29E-01 Aulchenko(2009) 
HDL rs3890182 ABCA1 A 0.09 -0.1 3.00E-10 same 0.37 -0.03 2.60E-01 Kathiresan (2008) 
HDL rs2156552 LIPG A 0.2 -0.07 2.00E-07 same 0.03 0.07 2.80E-01 Kathiresan (2008) 
HDL rs4846914 GALNT2 G 0.42 -0.07 2.00E-13 same 0.58 0.0009 7.45E-01 Kathiresan (2008) 
HGT rs6763931 ZBTB38 A 0.48 0.07 1.40E-27 rs6440003 0.25 0.105 3.17E-03 Gudbjartsson (2008) 
HGT rs724016 ZBTB38 G 0.48 0.37 8.30E-22 rs6440003 0.25 0.105 3.17E-03 Lettre(2008) 
HGT rs798544 GNA12 G 0.72 0.06 6.50E-15 same 0.47 0.078 1.23E-02 Gudbjartsson (2008) 
HGT rs3748069 GPR126 A 0.73 0.07 4.50E-14 rs7755109 0.25 0.082 3.76E-02 Gudbjartsson (2008) 
HGT rs2282978 CDK6-GATAD1 C 0.37 0.06 9.80E-09 same 0.06 -0.141 3.80E-02 Gudbjartsson (2008) 
HGT rs4533267 ADAMTS17 A 0.28 0.06 3.30E-08 same 0.4 -0.0588 6.90E-02 Gudbjartsson (2008) 
HGT rs6060369 GDF5-UQCC C 0.36 0.44 1.40E-16 same 0.31 -0.06 7.20E-02 Lettre(2008) 
HGT rs1812175 HHIP C 0.81 0.08 9.70E-12 same 0.63 0.05 1.13E-01 Gudbjartsson (2008) 
HGT rs7153027 TRIP11-ATXN3 A 0.61 0.06 1.10E-10 same 0.77 -0.059 1.41E-01 Gudbjartsson (2008) 
HGT rs2562784 SH3GL3-ADAMTSL3 G 0.17 0.34 6.40E-08 same 0.42 0.043 1.89E-01 Lettre(2008) 
HGT rs7846385 PXMP3-ZFHX4 C 0.34 0.05 4.70E-08 same 0.16 -0.05 2.58E-01 Gudbjartsson (2008) 
HGT rs1042725 HMGA2 T 0.49 -0.48 2.70E-20 same 0.55 0.022 5.02E-01 Lettre(2008) 
HGT rs4743034 ZNF462 A 0.24 0.05 2.10E-08 rs12411264 0.14 0.03 5.57E-01 Gudbjartsson (2008) 
HGT rs10513137 ZBTB38 A 0.26 0.03 8.00E-08 same 0.09 0.03 5.60E-01 Kim(2009) 
HGT rs3760318 CRLF3-ATAD5 C 0.64 0.06 1.80E-09 rs7225461 0.56 -0.0158 6.44E-01 Gudbjartsson (2008) 
HGT rs6918981 HMGA1 G 0.21 0.02 2.00E-08 same 0.14 0.018 6.90E-01 Kim(2009) 
HGT rs4794665 NOG-DGKE A 0.53 0.04 9.90E-08 same 0.26 -0.008 8.13E-01 Gudbjartsson (2008) 
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HGT rs6830062 LCORL-NCAPG T 0.84 0.06 1.30E-10 same 0.94 0.016 8.34E-01 Gudbjartsson (2008) 
HGT rs967417 BMP2 C 0.57 0.04 1.50E-08 same 0.13 -0.006 9.14E-01 Gudbjartsson (2008) 
LDL rs4420638 APOE G 0.18 0.19 1.00E-60 same 0.21 0.365 1.13E-23 Kathiresan (2008) 
LDL rs12654264 HMGCR T 0.42 0.1 1.00E-20 same 0.42 0.133 1.66E-05 Kathiresan (2008) 
LDL rs157580 APOE G 0.33 -0.111 2.10E-19 same 0.32 0.0326 3.49E-01 Aulchenko(2009) 
LDL rs16996148 CLIP2-PBX4 T 0.06 -0.1 3.00E-08 same 0.17 -0.05 5.63E-01 Kathiresan (2008) 
LDL rs693 APOB A 0.49 0.12 1.00E-21 same 0.09 -0.026 6.43E-01 Kathiresan (2008) 
LDL rs174570 FADS2/3 G 0.83 0.11 4.40E-13 same 0.80 -0.0003 9.50E-01 Aulchenko(2009) 
TG rs16996148 CILP2-PBX4 T 0.06 -0.1 4.00E-09 same 0.17 -0.179 2.11E-05 Kathiresan (2008) 
TG rs780094 GCKR T 0.38 0.13 3.00E-14 same 0.27 -0.125 1.15E-03 Kathiresan (2008) 
TG rs17321515 TRIB1 G 0.4 -0.08 4.00E-17 same 0.7 -0.0928 7.04E-03 Kathiresan (2008) 
TG rs328 LPL G 0.13 -0.19 1.00E-28 rs10503669 0.98 0.143 1.51E-01 Kathiresan (2008) 
TG rs157580 APOE G 0.33 -0.069 1.20E-08 same 0.32 -0.034 3.30E-01 Aulchenko(2009) 
TG rs12130333 DOCK7 T 0.24 -0.11 2.00E-08 same 0.04 -0.07 3.48E-01 Kathiresan (2008) 
TG rs693 APOB A 0.49 0.08 2.00E-07 same 0.09 -0.05 3.63E-01 Kathiresan (2008) 
TG rs4846914 GALNT2 G 0.42 0.08 7.00E-15 same 0.58 -0.022 4.60E-01 Kathiresan (2008) 
TG rs10889353 DOCK7 C 0.32 -0.085 8.20E-11 same 0.23 0.023 5.06E-01 Aulchenko(2009) 
TG rs17145738 MLXIPL T 0.12 -0.14 7.00E-22 same 0.14 -0.029 8.20E-01 Kathiresan (2008) 
URT rs505802 SLC22A12 T 0.7 -0.06 2.00E-09 rs10897518 0.97 -0.64 3.14E-17 Kolz(2009) 
URT rs17300741 SLC22A11 A 0.51 0.06 7.00E-14 rs12362644 0.71 0.162 8.16E-05 Kolz(2009) 
URT rs780094 GCKR T 0.42 0.05 1.00E-09 same 0.18 -0.082 9.73E-02 Kolz(2009) 
URT rs1165205 SLC17A3 T 0.46 -0.09 4.00E-27 same 0.23 0.04 3.50E-01 Dehghan(2008) 
Table 5.6: Comparison of effects and allele frequencies in Caucasians and Kosraens for known associated loci.  
1
Allele: the effected allele 
2
On 500K?: if the SNP from the outbred population study is on the 500K Affymetrix chip used in the Kosrae study “same” is indicated. If not, then a proxy SNP 
(r
2
>0.95 between the proxy SNP and the outbred population SNP) that is on the 500K Affymetrix chip is listed.   
3
Study: The outbred population studies used for this analysis are given in the references (Frayling, 2007)(Loos, 2008)(Ridker, 2008)(Kathiresan, 




(Lettre, 2008, Kathiresan, 2008, 
Frayling, 2007, Loos, 2008, 
Ridker, 2008, Aulchenko, 2009, 
Gudbjartsson, 2008, Kim, 2010, 
Kolz, 2009, Dehghan, 2008). 
For SNP‟s not directly typed on 
the Affymetrix array, 
association results are reported 
for a proxy on the Affymetrix 
chip with strong correlation 
(r
2
>0.95) to the original SNP in 
both HapMap Caucasian (CEU) 
and Asian (CHB, CHD, JPT, GIH) panels. Of the 53 SNP‟s, only 21 were detectable on 
Kosrae at nominal significance, indicating that more than half the associated SNP‟s were 
tagging causal variants that were either too rare to be detected or not present on the 
Island.  Sixteen of the 21 detectable SNP‟s on Kosrae had effect sizes in the same 
direction as those SNP‟s in the Caucasian cohorts (p<0.01) and 5 were in the opposite 
direction. Of the former set of 16 SNP‟s, 12 had stronger effect sizes on Kosrae, which is 
a greater number than expected by chance (p<0.027)   
 
Figure 5.3 Comparison of effect sizes for known loci in 
outbred populations on Kosrae. Effect sizes (the linear mixed 
model regression coefficient) on Kosrae (Kos on the y-axis) and 
in outbred populations (EU on the x-axis) for 16 genome-wide 
significant SNP’s from outbred population studies, where the 
signals are nominally significant on Kosrae and in the same 
direction, are plotted. A fitted line shows the cases where the 
effect size is stronger in the outbred population (blue) and on 




We describe a GWAS in a population-based cohort with extensive family structure and 
explore the value of genetics studies in a extreme populations isolate. Our goal was to 
take advantage of the population genetic features such a population offer, while 
maximizing power to detect association using mixed models. The analysis and re-analysis 
of 30 biomedical traits from the island using the more powerful mixed-model approach 
yielding 13 significant hits, only one of which had been detected by other methods. More 
importantly, were the discovery of a putative novel association for height, HBA1C and a 
novel long shared haplotype that accounts for ~20% variance in uric acid levels on the 
Island.  
 
These three novel associations exemplify both the limitations and opportunities for 
performing genetic mapping in isolated populations. We have demonstrated association 
for height in a region not previously observed, despite multiple large-scale genetic studies 
in Caucasians (Hirschhorn, 2009, Lettre, 2008, Weedon, 2008). It is possible that the 
underlying mutation is of stronger effect or higher frequency on the island, making it 
easier to detect. Alternatively, the causal variant may be Asian specific, or even private to 
the island.  If the latter case is true, then the signal is unlikely to be confirmed by 
replication. It should also be noted that the signal for the height SNP did not reach study-
wide significance and could represent a false positive.  
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On the other hand, we have observed a moderate signal for HBA1C (described elsewhere 
– pers. comm. Sasha Gusev) and an extremely strong signal for uric acid level, both also 
present in outbred, Caucasian populations, which we could refine by a IBD-based 
haplotype fine-mapping facilitated by the abundance of long shared haplotypes in 
isolated populations (Bonnen, 2006 ,Kolz, 2009). Further, since the uric acid haplotype 
tags only one of the two Caucasian variants in the same region previously known, our 
findings support independence between the two reported signals in the region.  Finally, 
the strong effect size of the haplotype is beyond the combined effects of  variants 
affecting uric acid level previous discovered (Kolz, 2009,  Dehghan, 2008). 
 
In conclusion, it is worthwhile reviewing our work in the context of recent ideas and 
results in association analysis. Specifically, the emerging picture is that despite 
comprehensive scans of association with common SNPs of multiple complex phenotypes, 
only a limited fraction of their heritable component has been identified(Frazer, 2009, 
Hindorff, 2009). Expanding the search for associated alleles to variants that are rare in the 
general population provides another piece of this heritable component, with multiple gene 
sequencing studies implicating such variants with moderate to high penetrance 
(Fearnhead, 2004 ,Cohen, 2004 ,Kotowski, 2006 ,Romeo, 2007, Marini, 2008). Our 
experiences in association testing in an isolated population can serve as a model for other 
studies of similar cohorts. Methodologically, mixed-models optimally extract association 
information from such samples. More importantly, in terms of study design and choice of 
cohort, we observe some of the previously theorized advantages and limitations of 
isolated populations. We showed that some variants that are associated to traits in other 
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populations do not replicate on Kosrae and this was due to bottleneck effects rather than 
lack of power. On the other hand, observed associations show strong effects and 
statistical support for a cohort of this size, potentially due to increased genetic and 
environmental homogeneity. Finally, as GWAS cohorts increase in size to the 6-digit 
range, and inclusion of somewhat related individuals becomes a practical modus 











Crohn's disease (CD) is a chronic inflammatory disorder of the gastrointestinal tract, 
which is thought to result from the effect of environmental factors in a genetically 
predisposed host. An epidemiological feature of CD is that it has highest prevalence 
among individuals of Ashkenazi Jewish (AJ) descent, occurring two to four times more 
frequently than in non-Jewish Caucasian populations. Three coding variants of the NOD2 
gene have been reported as independent disease-predisposing mutations for CD. 
Confirmation studies have shown, however, that these susceptibility loci have similar 
allele frequencies and magnitudes of the effect and are unlikely to contribute to the 
excess prevalence of the disease in the AJ population. Therefore, involvement of other, 
yet unknown, genetic variants unique to this population is hypothesized (Sugimura, 
2003). 
 
Here we analyzed CD in seven Ashkenazi Jewish cohorts, under a combined-analysis 
strategy. We generated a population specific reference panel for this dataset and impute 
m. As positive controls, we observed two genome-wide and six strongly significant 
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associations with known loci for Crohn‟s disease. In addition, we refined a broad signal 
peak for Crohn‟s disease at the NOD2 locus on chromosome 16 using analysis of 
identity-by-descent (IBD) shared genetic segments. We identified a second 13% carrier 
frequency haplotype ~1MB upstream of the top SNP in the region, which is independent 





We performed a population-
based screen of Ashkenazi 
Jewish (AJ) individuals by 
combining six New York-
based and one Israel-based 
screenings - see Table 6.1. 
Self–reported family 
relationships were recorded 
and only individuals who 
self-identified as AJ (or had 
at least one AJ grandparent) were used in the study. The cohorts comprised samples 
from; the NIDDK IBD genetics consortium, only persons with Jewish ancestry, obtained 
from dbGAP (Study accession: phs000130.v1.p1) -- NY1; Yale University (pers. comm. 
 Ntotal NCD cases Nnon-CD cases Ncontrols Platform 
NY1 828 397 - 431 Illumina 300k 
NY2 59 59 - - Illumina 1M 
NY3 136 136 - - Illumina 550k 
NY4 173 113 - 60 Affymetrix 500k 
NY5 1,067 261 806 - Affymetrix 6.0 
NY6 651 - - 651 Affymetrix 6.0 
TA1 397 - 200 197 Illumina 300k 
Total 3,311 966 1,009 1,339  
Table 6.1 Study participants from nine groups successfully 
genotyped on either an Illumina or Affymetrix platform. 
Screenings in nine centers based in New York (NY1-7) or Israel 
(TA1). For each screen, the total number of individuals examined is 
shown (Ntotal), in addition to any Crohn’s disease cases (NCD_cases), 
non-Crohn’s disease cases, which are a mix of Parkinson’s disease, 
Schizophrenics, Type-II Diabetes and Dystonia cases, (Nnon-CD_cases), 
and non-diseased controls (Ncontrols). . For each cohort, the platform 
used for genotyping is shown (Platform). 
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Judy Cho) -- NY2;  the Children‟s Hospital of Philadelphia (CHOP) (pers. comm. Hakon 
Hakonarson) – NY3; Mount Sinai Medical School (pers. comm. Inga Peters and Laurie 
Ozelius) – NY4-5; Albert Einstein College of Medicine (pers. comm. Nir Barzilai) – 
NY6 and the Hebrew University of Jerusalem (pers. comm. Ariel Darvasi) –TA1. The 
total number of AJ individuals from the seven screens was 3,311, where 966 were 
Crohn‟s disease cases and 2,345 were either non-Crohn‟s disease cases or non-diseased 
controls (1,009 and 1,339, respectively).   
 
Confirming Ashkenazi ancestry of study participants 
 
To confirm the AJ ancestry of the all the samples in the combined cohort we performed a 
principal component analysis (PCA) plotting the samples with the three continental 
HapMap reference panels (CEU, YRI and ASN (combined JPT+CHB) and seven panels 
from the Jewish HapMap (JHapMap) consortium consisting of one Ashkenazi Jews, one 
European Jewish, three Middle Eastern and two Sephardic Jewish panels. Figure 6.1 
shows the first and second eigenvectors of the PCA. Figure 6.1(A) shows the separation 
the three continental groups, where all except eight of the AJ samples cluster with the 
CEU Hapmap reference panel as expected. Figure 6.1(B) shows the same graph with the 
outlier YRB and ASN samples removed.   ~80% of individuals (n=2,661) in the AJ 
sample form a distinct cluster with the Ashkenazi Jews from JHapMap along the first 
principal components axis (PC1) as compared to both non-AJ Jews and individuals with  
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Figure 6.1 PCA analysis of AJ samples. (A) A principal component analysis graphs showing the first (x-
axis) and second (y-axis) eigenvectors plotting all 3,490 AJ samples (SAMPLE). Also included and color-
coded in the graphs are the four HapMap reference samples; CEPH-Utah (CEU), Yoruban-Nigeria (YRB) 
and the combined (Han Chinese and Japanese) Asian samples (ASN); and seven Jewish samples from the 
JewishHapMap project, consisting of Ashkenazi Jews (ASHKENAZI), one European Jewish (ITALIAN), 
three Middle Eastern (SYRIAN, IRAQI and IRANIAN) and two Sephardic Jewish cohorts 
(SEPH_TURKEY and SEPH_GREEK). (B) The same graph excluding the YRB and ASN outlier groups. 
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no Jewish ancestry (CEU), where the AJ cluster has a higher score than any other cluster. 
Further, we could identify ~300 samples who were positioned between the AJ cluster and 
the non-Jewish cluster (CEU) on PC1 (see Figure 6.2(A)). Upon examining the 
distribution of PC1 values in these samples, three distinct modes were defined; Group 1 
(PC1 -0.005-0.018), Group 2 (PC1 -0.015- -0.006) and Group 3 (PC1 -0.03- -0.016) (see 
figure 6.2(B)). We postulated, based on previous PCA analysis of AJ individuals (Need, 
2009) that groups 2 and 3 might represent individuals with 75% (one non-AJ 
grandparent) and 50% (one non-AJ parent or two non-AJ grandparents) AJ ancestry, 
respectively. So as not to exclude these individuals with partial AJ ancestry, we devised a 
GWAS strategy, whereby we would perform association mapping in within each group 
independently to control for admixture effects, and combined the p-values from each 
group under a meta-analysis design to construct a single test score.  Further, we noted 






Figure 6.2 Clustering along PC1 for people with AJ (to the right) and without and Jewish (to the left) 
ancestry.  Samples that clustered along PC1 between the AJ cluster (bottom right) and CEU cluster 
(bottom left) are shown between the dotted grey lines (A). A histogram of PC1 values for the included 
samples show three distinct modes (Groups 1-3).  
. 
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would be under powered for detecting CD driven signal. To optimize the power in group 
3, and under the assumption that group 3 comprised individuals that were 50% AJ/50% 
non-Jewish ancestry, we added 100 randomly drawn controls from group 1 and 100 
randomly select non-Jewish controls from the HapMap CEU population to group three. 
The final count of CD cases/Controls in each group was; group 1 (100% AJ) 671/1,890, 
group 2 (75% AJ) 35/37 and group 3 (50% AJ) 80/247. 
 
Constructing an Ashkenazi genotype reference panel 
 
Due to low imputation quality for AJ samples imputed from any of the standard HapMap 
reference panels, we opted to construct a custom AJ reference panel for imputation. We 
selected a random 100 AJ samples from the NY6 cohort who had been genotyped on the 
Affymetrix 6.0 platform and also typed those individuals on the Illumina 1M platform.  
The raw data consisted of 100 individuals 
typed for 1,778,360 unique SNP‟s across both 
platforms. To test for difference in the quality 
of genotyping on the two platforms, we examined the concordance of the overlapping 
SNP‟s. Of the 268,907 SNP‟s present on both platforms, >99% were concordant across 
all individuals between platforms (excluding SNP‟s with 1 or 2 missing genotypes on 
either platform and „ambiguous SNP‟ that are A/T or C/G on the Affymetrix platform). 
Two individuals who were <99.5% concordance were excluded from the reference panel 
 Total Discordant 
SNP’s 268,907 15,956 
SNP’s X Ind’s 24,062,937  31,354  
Total concordance   0.9987 
Table 6.2 SNP concordance between platforms. 
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(see Figure 6.3(A)). In addition, 263/268,907 were <0.9 concordant between the 
platform, which extrapolates to an estimated <0.0001 SNP discordance between the two 






Figure 6.3 Individual (A) and SNP (B) concordance between the Affymetrix and Illumina platforms.  
 
also excluded SNPs that were homozygous heterozygote, had a minor allele frequency 
(MAF) <0.02 and a genotype missingness of >0.02. For those SNP‟s that had ≤ 0.02 SNP 
missingness, we ran imputed the missing markers using BEAGLE (Browning, 2007) 
across the reference panel. The final reference panel consisted of 98 individuals, and 




Figure 6.4 Schema of combined analysis quality control pipeline. 
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Imputation of genotypes from the Ashkenazi reference panel 
 
The AJ reference panel was then used as a training set to impute missing genotypes for 
the combined NY1-6 and TA1 datasets using BEAGLE (Browning, 2007). SNP‟s that 
were either low in frequency (MAF <0.01) or had a poor imputation quality score 
(r
2
<0.9) were excluded (see Figure 6.4). The final combined dataset of genotyped and 
imputed SNP‟s contained 1,068,161 SNP‟s across 3,211 AJ samples (935 cases and 2,276 
controls). 
 
Association mapping of CD in Ashkenazi Jews 
 
Prior to performing association mapping, non-AJ samples as determined by PCA analysis 
(see above) were excluded from the sample (n=251). In addition, to control for batch 
effects across the seven cohorts, markers that were association p<10
-5
 in a pairwise 
cohort-cohort association (stratified by CD case status), were also excluded (n=7,227), 
Figure 6.4. The final filtered dataset used for association mapping comprised 1,060,934 
genotyped and imputed markers across 2,960 individuals, divided into three groups 
according to AJ ancestry (see above).  
 
For association mapping, we first built a kinship matrix of pairwise identity-by-state 
metrics based the high-density markers for the entire sample, which was incorporated  
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Figure 6.5 Association mapping of Crohn Disease in Ashekenazi Jews. (A) QQ-plots of the 100%, 75% 
and 50% AJ ancestry groups (groups 1,2 and 3, respectively). The number of individuals in each group is 
shown and the inflation factor for the p-value distribution is given. In the case of group 3, the p-values were 
genomic control adjusted for overinflation. (B) A manhattan plot (left) and qq-plot (right) of the combined 
association score from all three groups. (C) The same as B, but with 526 markers around the region of 
NOD2 signal on chromosome 16 removed before association mapping. The qq-plot shows the p-value 
distribution before (gray) and after (black) NOD2 removal and the inflation factor is for the latter. 
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into the mixed model for association mapping for the three groups (Kang, 2010). The p-
values were combined across the three groups using METAL, which takes direction of 
effect into account and weights the groups by sample size (Willer, 2008). Figure 6.5(A) 
shows the qq-plots for 100%, 75% and 50% AJ ancestry groups (groups 1,2 and 3, 
respectively). In the case of group 3, the p-values were quite overinflated (λ=1.14) and 
were corrected by genomic control to approximate normality (Devlin, 1999). 
 
Observation of positive controls in Ashkenazi Jews 
 
Figure 6.5(B) shown the combined score from all three groups, and as positive controls, 
we observe two genomic regions exceeding our genome wide significance threshold of 
5x10
-8
. Top SNPs are in known loci for Crohn Disease, NOD2 (16q12; rs2076756; 
p<2.32x10
-20
) and IL23R (1p31; rs11209026; p<9.42x10
-9
) (Barrett, 2008). In addition, 
we see 6 other signals for known loci p<10
-4
; ATG16L1 (2q37; rs2241880; p<2.88x10
-6
), 
IL3 (5q31; rs3091338; p<4.86x10
-5
), ZNF365(10q21; rs1076165; p<9.31x10
-6
), 





) and NKX2-3 (10q24.2; rs11190141; 9.8x10
-5
) (Barrett, 
2008)(Parkes, 2007). Finally we observed an interesting novel region approaching 
genome wide significance on chromosome 8q24 rs2922500 (chr8:134,676,639; 
p<8.36x10
-8




Haplotypic fine mapping of the NOD2 locus 
 
We performed haplotypic mapping on the broad peak at the NOD2. Haplotype mapping 
has been previously described in Chapter 2. Briefly, common shared long-range 
haplotypes were detected via pair-wise IBD genetic segment matching between all 
individuals in the pedigree using the GERMLINE software (Gusev, 2009). The IBD 
segments were at least 3cM in length and allowed for up to 1% mismatching due to 
genotyping error.  IBD segments were then clustered to groups of similar haplotypes, 
with >500kb overlapping sequence and sharing >99% sequence identity, as described in 
detail previously (Kenny, 2009). Clusters of shared haplotypes were then independently 
mapped to Crohn‟s disease which identified a single strong mapping cluster, where the 
specific sharing boundaries of the 253kb haplotype mapped to a sub-region (chr16:48.1-
48.4) of the Crohn‟s GWAS signal peak, ~1MB upstream of the top SNP in the region. 
This novel "CD haplotype" (rs1420682 to rs11076503) is unique to a group of 396 
individuals (carrier frequency 0.13), is strongly associated to CD (p<8.1x10
-17
), and has 
an odds ratio of 1.47.  A logistical regression of CD with the CD haplotype as a covariate 
has little effect on the signal for the top NOD2 SNP (p<1.45x10
-17
). Likewise, a logistical 
regression of CD with the top NOD2 SNP (rs2076756) as a covariate has little effect on 
the CD haplotype (p<3.45x10
-15
), indicating that the two signals are independently 
associated to CD. A genome-wide scan of Crohn‟s disease using both the CD haplotype 
and rs2076756 revealed no remaining genome-wide significant signal in the region 
(p<10
-4
), indicating that rs2076756 and the CD haplotype likely capture the full signal in 




We describe a GWAS for Crohn‟s disease across seven Ashkenazi Jewish cohorts using a 
combined analysis strategy and a population specific reference panel for imputation. The 
analysis yielded 8 positive controls, 2 of which were genome-wide significant, and an 
interesting novel region of borderline significance on chromosome 8q24.  More 
importantly, haplotypic fine mapping of the strong signal peak on chromosome 16 




Chapter 7 : Discussion 
 
 
Implementing improved analytical strategies for founder populations 
 
The goal of this thesis was to explore the opportunities for analyzing founder populations 
to detect causal variants affecting complex disease. The idea was to leverage the unique 
features of such populations for exploring genetic variations, in particular rare variations, 
while overcoming the technical challenges inherent to their genetic architecture. We first 
tested specialized strategies in a small, highly related, founder population. We then 
demonstrated the extensibility of these approaches by successfully applying them in a 
larger, less extreme, founder population.   
 
Improved methodology for genotypic mapping 
 
GWAS of samples containing extensive relatedness, which is usually the case for founder 
populations, have been traditionally analyzed using family-based methods 
(Gudmundsson, 2007, Ober, 2001, Lowe, 2009). However, extensive analysis at a single 
locus level has previously shown that family-based tests have lower power than 
population-based methods, such as mixed-models, in the presence multiple levels of 
relatedness (Yu, 2006), and we have observed this on Kosrae (Lowe, 2009). The 
statistical advantage of mixed-models comes at the cost of higher model complexity, 
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resulting in a lack, until recently, of mixed model methods capable of handling large-
scale human datasets in a computationally efficient manner.  
 
Here we have demonstrated the improved power for mixed models in the context of the 
extensive, multi-generational relatedness found on the Island of Kosrae.  We focused 
specifically on a range of p-values not yet explored and showed that mixed models gave a 
>2-fold boost in power over other methods. Importantly for the reduction of false 
positives, the test statistic produced is uniformly distributed, with no artificial 
overdispersion of the p-value.  The improvement in power is due in part to the utilization 
of variation both within and between samples (captured in the kinship matrix) and also 
the ability to include all samples in the analysis. Our empirical results on Kosrae show 
similar power to like-sized outbred populations and support the use of mixed-models for 
association in founder populations. 
 
Novel methodology for haplotypic mapping 
 
Much of the work for association analysis has been focused on the effects of single SNPs. 
We provide a more extensive approach that considers long range haplotypes, identical-
by-descent, across multiple samples, as genetic markers. Such recently arising haplotypes 
are likely to carry rare mutations, which are the focus of sequencing endeavors (see 
below). As proof of the pudding, we provide examples for three novel signals, mapped by 
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association to long range haplotypes on Kosrae, with two casual mutations confirmed by 
sequencing.   
 
This approach was aided by a high degree of relatedness and founder effects on Kosrae 
that resulted in abundant, long haplotypes in our study population (Bonnen, 2006). 
However, recently, tracks of relatedness in regions of the genome have also been seen in 
less extreme founder population (Kong, 2008), and even in apparently unrelated 
populations (Frazer, 2007).  We therefore tested the haplotype mapping approach in a 
canonical founder population, with less extreme founding effects than are seen on 
Kosrea, the Ashkenazi Jewish population. We demonstrated the extensibility of our 
method in this less founder population by mapping a novel haplotype for Crohn‟s disease. 
 
A key advantage of haplotypic mapping compared to genotypic mapping, is the 
additional positional information, where the physical haplotype boundaries, as well as the 
specific carriers, are explicitly identified – a useful roadmap of follow up sequencing. We 
also demonstrated in three of the cases that our method can be used to dissect multiple 
signals at the same locus.  In addition, since the long shared haplotypes were constructed 
from SNP-chip data, this approach can complement a traditional association mapping 
method. However, the method is limited to resolving very long haplotypes < 20 
generations old.  If a causal mutation arose more distantly and surrounding haplotypes are 
too short the method will not have any mapping power. 
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New biological insights  
 
Overall, a GWAS, using mixed models, of 30 metabolic traits on Kosrae yielded 13 
positive controls and 4 novel loci for height, haemoglobin A1C, uric acid and plasma 
plant sterol levels, 3 of the latter being refined by haplotype mapping. The same 
approaches applied in an Ashkenazi Jewish cohort for a single trait, produced two 
positive controls, a novel hit region and a novel independent associated haplotype at one 
of the positive control loci.  
 
Effect sizes in founder populations 
 
To examine the genetics of common traits on Kosrae as compared to outbred populations, 
we assessed the effect sizes observed on Kosrae for known loci discovered in studies 
using outbred, mainly Caucasian populations. We showed that some variants that are 
associated to traits in other populations do not replicate on Kosrae, due to bottleneck 
effects rather than lack of power. On the other hand, observed associations show strong 
effects and statistical support for a cohort of this size (with the caveat that the number of 
markers we were able to compare is small). While this empirical observation is open to 
interpretation, and somewhat anecdotal, it does indicate the benefit of increased genetic 
and environmental homogeneity for variant discovery. 
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Detection of rare variation 
 
Using the haplotypic mapping method, it was possible to detect a relatively rare (minor 
allele frequency < 1%) causal genetic variants. Expanding the search for associated 
alleles to variants that are rare in the general population provides another piece of the 
heritable component of disease, with multiple gene sequencing studies implicating such 
variants with moderate to high penetrance (Fearnhead, 2004, Cohen, 2004, Kotowski, 
2006, Romeo, 2007, Marini, 2008). The new era of high throughput sequencing returns 
the emphasis to rare variation, playing to the strength of isolated communities.  
 
Limitations of founder populations studies 
 
Replication of results in the hands of a different researcher is a cornerstone of good 
science. Genetic association signals for alleles that are common and shared across 
populations and continents have been successfully replicated. In the Kosraen study, such 
replication is expected to be more challenging, especially for rare, newly arisen variants, 
as some variants are expected to be limited to Pacific islanders or East Asians that are 
under-represented in large association studies. We rely on increased participation of these 
groups in such studies, facilitating replication in the future. Furthermore, as linkage 
studies have succeeded to establish over the last two decades, there are multiple options 
to support a genetic effect of a variant, even when it is a family-specific mutation. These 
criteria should hold for the “extended family” of Kosrae. Mutations can be supported by 
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evidence from annotation, other variants in the same gene, or pathways with observed 
enrichment of causal variation and functional follow-up in the lab.  
 
Imputation of unobserved genotypes of common alleles has been previously used in 
general, outbred populations. This approach relies on the ancient shared origin of an 
imputed sample and reference individuals, forfeiting the option to impute the low-
frequency alleles that have arisen since their common ancestor. The strategy requires the 
availability of a densely genotyped reference panel, such as the HapMap project (Frazer, 
2007). However, there is reduced portability of this approach to populations that are, 
compared to available reference panels, genetically distinct, such as founder populations. 
This leads to a reduction in imputation accuracy, and a consequent reduction in statistical 
power for imputation based association mapping. We have observed poor imputation 
power for both founder populations used in this study, especially on Kosrae. This 
problem is expected to be somewhat alleviated as more populations are added to the 
existing referencing panels, such as the Jewish HapMap (pers.comm. Harry Ostrer).  In 
addition, the abundance of homozygosity (Morrow, 2008) and long-range haplotypes 
(Kong, 2008) found in population isolates will facilitate the next generation of tools for 
the detection of rare disease-associated haplotypes. For example, methods for imputation 
based on IBD segments are expected to capture many recently arising mutations, thus 





Hand in hand with the explosion of genotype data in the past few years, many exciting 
technical advances have been made in the area of sequencing. Recently, there has been a 
fundamental shift away from traditional Sanger sequencing towards so-called “next-
generation sequencing” (NGS) technologies for genome analysis. These newer 
technologies constitute various strategies that rely on a combination of template 
preparation, sequencing and imaging, and genome alignment and assembly methods 
(Metzker, 2010). The production of large numbers of low-cost reads make the NGS 
platforms useful for many applications, such as cataloguing transcriptomes (RNA-
sequencing) or epigenetic marks (ChIP-sequencing, Methyl-sequencing), and  re-
sequencing target areas of a genome. The broadest application of NGS is in the 
sequencing of human whole-genomes to enhance our understanding of how genetic 
differences affect health and disease.  
 
Many of the initial whole-genome sequencing studies have focused on proof-of-
technology, and presently, high-quality personal genomes exist from representatives of 
the major continental groups (Wheeler, 2008, Ahn, 2009, Bentley, 2008, Kim, 2009, 
Levy, 2007, McKernan, 2009, Wang, 2008). The major advance offered by NGS is the 
ability to produce enormous volume of data cheaply, the lowest published cost being 
~$5K for a whole human genome (Drmanac, 2010), down from $1 in 2004 to a small 
fraction of a cent (<$0.000002) per base pair today.  
 121 
 
Current approaches for sequence-based mapping of human disease included whole-
exome capture in a small number of individuals. This approach has been successful in 
identifying causal variants in monogenic disease cases (Ng, 2010). However, such studies 
ignore non-coding regions and do not yet scale to large populations (Galvan, 2010). For 
complex traits, a popular approach is the targeted re-sequencing of candidate loci under 
local signal peaks detected in GWAS across many individual (Cohen, 2004). However, 
this strategy scales poorly for multiple traits and across a large number of loci and 
pursuing such a strategy genome-wide is still resource intensive, despite a considerable 
drop in sequencing costs. We suggest an alternative paradigm for population-based 
sequencing that plays to the strengths of a small, extreme isolate population, such as 
Kosrae.  
 
A population-based paradigm for sequencing in founder populations 
 
Our strategy leverages the current multi-trait GWAS data and the inherent relatedness of 
the cohort with the resultant enrichment of IBD long genetic segments on the island. We 
devise an approach to sequence a small number of individuals, forming a population 
specific reference panel of the island. In conjunction, we can use the GWAS SNP‟s to 
construct a genomewide, population-wide catalogue of long segments that are IBD across 
individuals. Finally, we can propagate any reference panel variants to non-sequenced 
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individuals through imputation based on the IBD segments for mapping across multiple 
traits.  
 
Our intial estimates show that sequencing ~80 individuals selected for most IBD sharing 
on Kosrae will capture > 80% of the total variation on the island. In other words, a 
modest 0.25TB sized reference panel has the potential to yield >7TB of imputed 
sequence. This means that in Kosrae, we can cover the entire genome sequence with 
resources that are sufficient for only targeted, candidate gene sequencing of similar 
sample sizes in most populations, as they lack these characteristics of isolation. Analysis 
of this genetic data in conjunction with phenotypic data in Kosrae holds the potential 




This study of founder populations has highlighted the usefulness of understanding the 
population-genetic properties of a particular study population for recognizing the features 
and limitations of disease mapping in that population. As the field of human genetics 
moves forward to explore new and expanded sources of variation, models of these 
population-genetic features offers a context with which to interpret the data. Because the 
full genetic history of the human population is unknown, population-genetic models can 
be used instead to generate plausible theories. Such models begin from the perspective 
that the factors that affect the genealogical descent of a disease mutation, such as 
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bottlenecks, migrations and the recombination landscape, ultimately affect the 
distribution of the variant across contemporary individuals and populations. Thus, the 
properties of risk variants simulated under such models can be used to evaluate strategies 
for detecting them. Further, the models themselves will be calibrated and improved as 
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